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Primary glioblastoma multiforme is the main primary brain cancer in adults. It is a diagnosis that 
carries with it a devastatingly poor prognosis. Best current practice, consisting of debulking surgery, 
radiation therapy and Temozolomide chemotherapy, results in a mean overall survival of 15-20 
months after diagnosis. There is no standard treatment for relapsed high grade glioma. The most 
promising chemotherapy regimens, using Temozolomide, Bevacizumab and Irinotecan, have 
resulted in a mean overall survival of 8.8 to 9.3 months from salvage therapy. Several clinical studies 
have reported a mean overall survival of 3.9 - 12.5 months after salvage hypo-fractionated radiation 
therapy.  The aim of salvage treatment for high grade glioma patients is the palliation of symptoms 
and maintenance of quality of life.  
The research presented in this thesis follows the journey of seven patients with recurrent high-grade 
glioma through their salvage radiation therapy and beyond at Auckland Radiation Oncology between 
September 2014 and December 2015. The objectives were to 1] gain an insight into the impact of 
hypo-fractioned re-irradiation on Health Related Quality of Life during and after the completion of 
salvage treatment and to 2] determine the nature and severity of tumour associated symptoms 
before, during and after completion of hypo-fractioned re-irradiation.  
A prospective observational study design was used with a variety of methods of gathering 
information to document the patients’ journeys. Patients completed the European Organisation for 
Research and Treatment of Cancer (EORTC) QLQ-C30 and BN-20 quality of life questionnaires to 
capture self-reported severity of symptoms scores, overall health and quality of life at baseline, 
during and after treatment. The author attended follow-up consultations with the radiation 
oncologist to gain an insight into the disease and treatment-related symptoms and their effect on 
day-to-day life. Any notes taken during the consultations were cross referenced with notes from the 
treatment radiation therapists and radiation oncologist in the patient file. The author also reviewed 
patient notes and CT and MRI scans to understand the disease trajectory from primary diagnosis to 
recurrence and gain details of the radiation therapy treatment plan. The intent was to document 
treatment-related side effects using the Common Terminology for Adverse Events (CTCAE) adverse 
events criteria. CTCAE scoring was discontinued after the first patient due to the burden of an 
additional interview with these vulnerable patients and the similarity of the CTCAE items to those 
covered in the quality of life questionnaires. Side effects were also discussed during consultations 
with the radiation oncologist, which the author attended.  
The journey of each of the seven patients was very distinct. Patient expectations regarding their 
health and quality of life throughout salvage therapy depended on a combination of age, stage in 
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life, time to relapse, severity of disease symptoms and the extent to which they had accepted their 
prognosis. All of the patients experienced some level of psychosocial distress. Six patients reported 
at least “a little worry or depression”; patients also reported feeling at least “a little uncertain about 
their future”.  
Salvage re-irradiation to a median dose of 35Gy in 10 fractions was found to be well tolerated 
although a decrease in overall health and quality of life from baseline was reported in five of the 
seven patients during the two weeks of treatment. Fatigue, exacerbation of tumour symptoms and 
disruption to daily life worsened during radiation treatment. A majority of patients responded to 
salvage re-irradiation with a partial response and six patients had further salvage chemotherapy. 
Most patients reported an increase in or reasonably stable overall health and quality of life scores 
after completion of radiation treatment.  
Limitations of the study included cohort demographics and a short and varied follow-up time. 
Because of the time constraints of an honours thesis project, only a small number of patients 
participated. Patients enrolled early in the study were followed for a much longer period of time (up 
to 15 months) than patients who enrolled later (minimum of five months). Even though this small 
cohort was very heterogeneous with respect to age, stage in life, time to relapse and salvage 
treatment, they all attended a private clinic and most likely belonged to a higher socioeconomic 
class where the pressures of having to keep working to provide for the family were not key factors. 
The cohort also lacked ethnic diversity as all patients identified themselves as NZ European. 
The patients themselves were supposed to fill in quality of life questionnaires at the start, during 
treatment and follow. This did not happen for all time points for all patients because in a few 
instances the author was not advised of a change in follow-up appointments or could not be 
released from clinical duties to hand out the questionnaires and in some cases patients were too sick 
to fill them in. 
Overall, the experience of this small cohort of patients suggests that hypo-fractionated radiation 
may be a salvage therapy option for at least some patients with relapsed high grade glioma. One of 
the major costs of salvage radiation therapy for patients is disruption to everyday life due to the 
logistics of attending daily treatment sessions. It is therefore appropriate that it is delivered over a 
relatively short period of two weeks. The study further identified the need for more research into 
the physical and psychosocial wellbeing of high grade glioma patients and the best ways to support 
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 Chapter 1   Introduction  
Despite significant research and aggressive treatments, high grade glioma is an incurable cancer 
which can be palliated with hypo-fractionated radiation therapy upon recurrence. There are some 
concerns that re-irradiating parts of the brain may cause radiation necrosis, resulting in 
unacceptable neurological and cognitive symptoms [1]. This thesis describes the journey of seven 
high grade glioma patients through their salvage radiation treatment and the period immediately 
after completion of treatment. 
Primary glioblastoma multiforme (GBM) is the most frequently diagnosed primary brain cancer in 
adults and has a devastatingly poor prognosis. Current best practice, consisting of debulking surgery, 
radiation therapy and Temozolomide chemotherapy, results in a mean overall survival of 15-20 
months after diagnosis [2]. Primary glioblastomas develop with a short clinical history and without 
evidence of a previous low grade lesion, and is the most common type in older adults (over 50yrs) 
[3]. In younger patients glioblastoma may develop through progression from a pre-existing lower 
grade glioma [3]. In addition, brain tumours have a large negative impact on patient wellbeing and 
quality of life. Clinical research therefore focuses on increasing overall survival and delaying 
progression as well as on palliation of symptoms and maintaining or improving patient quality of life 
[4].  
This chapter describes the incidence and symptoms associated with GBM, key diagnostic imaging 
modalities, primary and secondary treatment options and the impact of the tumour and its 
treatments on patients’ quality of life. 
1.1 Incidence 
The incidence rate for primary brain cancer in New Zealand is 5.5 per 100,000 people (5.3 for Maori 
and 5.5 for non-Maori). The rates are significantly higher in males than females, 6.4 and 2.8 per 
100,000 people respectively. Internationally, brain cancer is not a common cancer, in New Zealand 
brain cancer accounted for 1.4% of all cancer registrations in 2012 [5]. Despite the low incidence 
rate brain cancer is disproportionately represented in the mortality rates. It is the 7th most common 
cancer death in males and the 10th most common cancer death in females. In 2012, 309 people were 
diagnosed with primary brain cancer and 278 people died of the disease in that year, accounting for 
3.1% of all cancer deaths [5]. Gliomas may be low or high grade depending on histopathological 
features. In New Zealand, primary brain cancer reporting is not stratified according to grade. High 
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grade glioma (WHO grade III and IV) account for 50% of primary malignant brain tumours, 80% of 
those are GBM [6].  
1.2 Symptoms 
Although any cancer diagnosis is life changing, a brain tumour is possibly the most devastating by 
virtue of its location. Brain tumours can affect a person’s ability to walk, talk, feel, communicate, 
remember and think. Many of the symptoms are due to compression of the brain against the skull or 
by obstructing the ventricular system which results in increased intracranial pressure. Increased 
intracranial pressure may cause headaches, vomiting, visual disturbances, and cognitive and 
behavioural changes [7]. Symptoms of the disease have common elements but differ based on the 
location of the tumour inside the brain. Frontal lobe tumours for example may cause personality 
changes whereas occipital tumours may cause visual deficits [7].  Figure 1.1 provides a general 
overview of human function and behavioural locations in the brain.  
 
Figure 1.1: Major parts of the brain and the functions which the perform [7]. 
The symptoms associated with brain tumours have a very serious impact on daily life for patients 
and their families. The aim of any cancer treatment should extend beyond prolonging survival. 
Treatment of high grade gliomas is not curative and therefore aims to palliate symptoms of the 
disease and thus maintain or improve quality of life. Health-related quality of life (HRQOL) has 
3 
 
become an increasingly important endpoint in all cancer studies, next to outcome measures such as 
overall survival and disease-free survival. This is particularly important for people with tumours that 
are incurable such as high grade glioma [8].   
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1.3   Detection and Diagnosis 
1.3.1. Anatomical imaging: computed tomography (CT) and magnetic resonance imaging 
(MRI)  
Differential diagnosis is crucial as this informs the most appropriate line of treatment. At 
presentation a complete history and physical examination are taken. As the presentation of brain 
tumours is very varied, a CT scan is usually performed to confirm the presence of a mass and rule out 
other pathology such as a stroke [9]. CT scans are relatively inexpensive and are widely available 
throughout New Zealand. However, it can be difficult to accurately visualise the extent of the 
tumour on CT. Figure 1.2A is a picture of a GBM visualised on a CT scan. The CT scan is usually 
followed by an MRI scan as these more reliably define the extent of the tumour and any associated 
swelling (peritumoural oedema). Different MRI sequences can be used to determine the extent of 
the tumour (Figure 1.2B) and peritumoural oedema (Figure 1.2C). MRI and CT images can be overlaid 
using radiation therapy planning software to determine the area where radiation needs to be 
delivered. A red circle is used to highlight the area of abnormality (Figure 1.2D). A surgical resection 
is done where possible to obtain a histopathologic diagnosis as this will predict clinical behaviour 
and prognosis of brain tumours. At Auckland Radiation Oncology another MRI is usually done 
following surgery to assess the extent of the resection and aid in planning of radiation therapy.  
 
Figure 1.2: Example of different images of the same brain tumour. The tumour of patient GBM02 
was imaged at the time of diagnosis. A. CT scan, B. T1 MRI scan, C.T2 MRI scan, D Overlay of all 
three images.   
 
New MRI techniques are also evolving. Diffusion MRI provides information on cellular density and 
perfusion MRI provides functional information on the development of new blood vessels 
(angiogenesis) which is helpful because increased angiogenesis may be indicative of tumour 




1.3.2 Functional imaging: positron emission tomography (PET) 
Tumours take up large amounts of glucose for energy and amino acids to make proteins in 
preparation for cell division [9]. PET measures the uptake of amino acids by using either 11C-
methionine (MET) or 18F-fluoroethyl-L-tyrosine (FET) to visualise the presence of actively 
metabolising cells rather than physical tumour mass which consists of actively dividing cells, inactive 
cells and dead cells [9]. As PET visualises actively metabolising tumour cells whereas MRI visualises 
physical tumour mass and associated swelling a comparison of FET-PET and MRI data of gross brain 
tumours has found that the size and geometric location of the gross tumour volume for radiation 
therapy planning differed between the two imaging modalities [10]. This affects radiation therapy 
planning which ensures that the tumour is treated to a high enough dose and normal brain tissue is 
spared. PET is also useful in distinguishing between tumour progression and treatment-related 
changes in the brain (pseudo-progression) that are not due to tumour progression [9]. Figure 1.3 (A-
C) shows images acquired of patient GBM05’s brain prior to the commencement of salvage therapy 
to distinguish areas of active tumour and radiation induced changes in the brain.  
 
 
Figure 1.3: Images of the tumour of patient GBM05. A. PET scan, B. CT scan acquired 




The treatment options for patients with high grade glioma can be divided into primary treatments 
for newly diagnosed patients and salvage treatments for patients with recurrent disease.  
1.4.1  Primary treatment options 
The goal of therapy for high grade glioma is the same as for all cancer patients: to prolong life whilst 
minimizing symptoms from either the tumour or the treatment. After diagnosis, progressive 
neurological deterioration can usually be stabilised or reversed, at least temporarily by treatment. 
Debulking surgery, radiation therapy and chemotherapy will decrease tumour burden and extend 
life by killing the tumour cells. Pharmaceutical interventions may also be used to minimise the 
symptoms of the brain tumour. The corticosteroid, Dexamethasone, is used to decrease brain 
swelling and thus intracranial pressure and the symptoms associated with that [11].   
Surgery allows for a histological diagnosis to inform treatment. More complete surgical resection has 
been associated with a better prognosis. In patients where complete surgical resection was possible 
median survival improved by 5-months compared with patients who received incomplete surgical 
resection [107]. Complete resection is rarely an option for high grade glioma patients as surgery is 
limited by tumour location and extent, patient status and risk of debilitating neurologic deficits. It is 
difficult to define the margins of the tumour because of their highly invasive nature. Generally, the 
more extensive the resection, the longer it takes for the tumour to return and cause symptoms. The 
vast majority of GBM patients therefore undergo debulking surgery which reduces the mass effect 
and pressure on the healthy brain tissue surrounding the tumour [2]. Recent developments using 
fluorescent imaging are currently being trialled to aid better visualisation of the tumours prior to and 
during surgery [12]. Infusion of biological agents such as chemotherapy and immunotherapy directly 
into the tumour bed at the time of surgery are also under investigation [12].  
Radiation therapy plays a central role in the treatment of high grade gliomas. Following surgery, 
radiation therapy with concurrent chemotherapy is the standard of care. The total radiation dose 
deliverable is limited by toxicity to normal structures (brain, brainstem, optics etc.) [108] Over the 
past decade with the advances in radiation therapy planning, treatment delivery and image 
guidance, radiation therapy delivery has become more precise, delivering a high dose to the target 
and minimising the dose to normal tissue thereby limiting acute and chronic radiation toxicities. The 
latest delivery technique is volumetric arc therapy (VMAT) which allows the beam to be highly 
modulated in order to cover the target volume and have a steep dose drop off to reduce dose to 
critical structures [13]. Wagner and colleagues [14] dual planned 14 consecutive patients with 
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malignant glioma using 3D conformal radiation then re-planned and used VMAT delivery for 
comparison. Both techniques achieved good coverage of the target as long as it was distant from 
critical structures in the brain (i.e. brainstem, optics). If the target volume was close to critical 
structures the 3D conformal plan achieved poor target coverage in order to keep critical structures 
within normal tissue tolerances for toxicity. VMAT achieved much better target coverage. Poor 
target coverage results in areas of the tumour being under dosed which will result in less cell kill in 
that area. VMAT can also be delivered more quickly than 3D conformal radiation therapy[14]. VMAT 
treatment can be delivered in 90-seconds whereas 3D conformal radiation therapy treatment 
delivery takes in excess of five minutes. VMAT minimises the amount of time that the patient is 
immobilised in the treatment position.  
The first step in creating a successful radiation therapy treatment plan is accurate tumour 
delineation. New imaging technologies such as perfusion MRI and FET-PET aid in the visualisation of 
tumours and research is ongoing to correlate these imaging modalities to treatment targets and 
clinical outcomes [15]. Improved treatment planning computer programs allow for the development 
of highly targeted treatment plans as well as accurate recording of dose to critical structures. This is 
particularly important when delivering multiple courses of radiation therapy over time. The 
treatment planning system, RayStationTM, allows doses from multiple courses of radiation therapy to 
be transferred (taking into account any anatomical changes as a result of further surgery) onto the 
current planning CT dataset [16]. RayStationTM is the treatment planning system used at Auckland 
Radiation Oncology.  
Stupp protocol: current gold standard of treatment 
Prior to 2009, standard treatment for newly diagnosed GBM consisted of debulking surgery and 
standard fractionated radiation therapy of 60Gy in 30 fractions, 2Gy per fraction, 5 fractions per 
week, over 6 weeks.  Stupp and colleagues set a new standard of treatment with their seminal Stage 
III randomised clinical trial (RCT) in 573 GBM patients, 286 of whom were in the radiation therapy 
(RT) only arm and 287 who were on the Stupp protocol [2]. This trial showed that adding concurrent 
and adjuvant Temozolomide to debulking and conventional 60Gy in 30-fraction radiation therapy 
increased the mean survival from 11.2 months to 14.6 months, with 27% (95% CI 22.2-32.5%) of 
patients still alive at 2 years (16% (95%CI 12.0-20.6%) at 3 years, 12.1% (95%CI 8.5-16.4%) at 4 years 
and 9.8% (95%CI 6.4-14%) at 5 years) after diagnosis compared with 10.9%(95%CI 7.6-14.8%), 4.4% 
(95%CI 2.4-7.2%), 3% (95%CI 1.4-5.7%) and 1.9%(95%CI 0.6-4.4%) of patients on the old “surgery and 
radiation only” regimen (p<0.001). Concomitant chemotherapy consisted of daily oral 
Temozolomide, 75 mg/m², 7 days per week from the first to the last day of RT, for at most 49 days. 
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After a 4-week break, patients received up to six cycles of adjuvant oral Temozolomide (150–200 
mg/m²) for 5 days every 28 days [2]. 
The new “Stupp” protocol, as it is referred to in the literature, has been used in a number of studies. 
Athanassiou and colleagues repeated Stupp’s protocol in a Stage II RCT with 65 patients in the RT 
only arm and 65 patients on the Stupp protocol and reported very similar mean overall survival data 
of 7.7 months for patients receiving radiation therapy only and 13.4 months for patients in the RT 
plus Temozolomide arm (p<0.001) [17]. A retrospective analysis of 249 patients reported a mean 
overall survival of 13.4 months (95%CI 10.9-15) for patients on the Stupp protocol (n=103) and 8.8 
months (95%CI 6.9-10.7)for patients on the RT only arm (p=0.006) [18]. Overall survival data from 
other trials report mean overall survival rates for patients on the Stupp protocol of 15.7 [19], 19.6 
months [20] and 21.1 months [20]. A summary of these trials is given in Appendix A. 
Temozolomide, given concurrently with radiation therapy as well as adjuvantly, after radiation 
therapy has been completed, has increased the life expectancy of newly diagnosed GBM patients by 
several months. Two clinical trials have investigated whether changing the dose schedule of 
Temozolomide may make a difference to patient outcomes; their results are summarised in Table 
1.1. Both trials compared a dose dense delivery where a high dose (150- 200mg) is delivered over a 
short period of time (five days once or twice a month) with metronomic delivery, where  a low dose 
is given continuously (50mg every day) [21,22]. The mean overall survival was slightly better for the 
dose dense arm in both trials but this difference was not statistically significant in the larger trial 
[22]. 
Table 1.1: The effect of different Temozolomide dosing schedules on patient outcomes. 
Comparison of TMZ dosing schedules  
















on days  1-28   




on days 1-7 and 15-21 
2100 42 
6.6 (4.2-7.8) 
No p value given 
17.1 (14.0-28.1) 






   
on days 1-21 












No. of pts = number of patients, PFS = progression free survival, OS = overall survival, 6m = six months, TMZ = 
Temozolomide  
Temozolomide is an alkylating agent which adds a methyl group to the purine base, guanine, forming 
O-6methylguanine in the DNA. Base methylation causes crosslinking of the polynucleotides of the 
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DNA double helix, which interferes with DNA replication and transcription, killing the cancer cells [3]. 
The methylated bases are successfully repaired by an enzyme called O-6-methylguanine-DNA 
methyltransferase (MGMT). Methylation of the MGMT promotor renders the enzyme inactive and is 
present in 35%-45% of high grade gliomas [3]. Patients with methylated MGMT promotor respond 
well to Temozolomide chemotherapy, whereas patients with normal MGMT are unresponsive and 
therefore have a poorer prognosis [3]. However, not all trials have determined the methylation 
status of their patients and generally those that do so have not stratified patient response to 
Temozolomide by methylation status. 
Adding chemotherapy drugs to the Stupp protocol 
Over the last five years many clinicians have added a range of cytotoxic drugs to the Stupp protocol 
to increase patient survival without jeopardising patient wellbeing. The results of these clinical trials 
are briefly described below and summarised in Appendix B.  
Bevacizumab is a humanised monoclonal antibody that specifically binds to and inactivates the 
angiogenesis-inducing cytokine, vascular endothelial growth factor (VEGF). VEGF is normally 
produced by endothelial cells lining the small blood vessels and capillaries. VEGF binds to specific 
VEGF receptors on the membranes of endothelial cells and this instigates a cascade of reactions 
which leads to the outgrowth of more capillaries (angiogenesis) along a concentration gradient of 
VEGF. In a healthy body this occurs only when more blood vessels are required for homeostasis. 
Many cancers, including high grade glioma, produce their own VEGF which, when bound to the VEGF 
receptor, promotes angiogenesis, allowing the tumour to grow beyond 2mm in size. Bevacizumab 
inhibits angiogenesis by “trapping” VEGF in the extracellular fluid, preventing binding to the VEGF 
receptor and angiogenesis [23]. 
The combination of Temozolomide and Bevacizumab was reviewed recently by Poulsen and 
colleagues, who reported a mean overall survival between 11.7 and 23 months from seven stage II 
and three stage III clinical trials [24]. The review concludes that about one third of patients respond 
to the addition of Bevacizumab and that some, but not other studies, report that adding 
Bevacizumab improves patient HRQOL. Two trials that directly compared the STUPP protocol and 
the addition of Bev found a significantly higher PFS for the BEV arm but not for the OS arm [25]. 
Most GBM patients will suffer from neurological and cognitive impairment to some extent due to 
the presence of the tumour but also from increased cranial pressure caused by oedema. 
Corticosteroids such as Dexamethasone are strong systemic anti-inflammatory agents that decrease 
oedema in the brain and improve the symptoms of increased intracranial pressure. However, 
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systemic corticosteroids have their own toxicity profile, which affect patient quality of life. The main 
symptoms include mood changes, depression, anger, anxiety, insomnia, trouble thinking, speaking or 
walking and weight gain. Bevacizumab has a corticosteroid sparing effect because it decreases 
oedema in the brain and as such can improve patient HRQOL. Toxicities associated with 
Bevacizumab include haematotoxicity (leukopenia, lymphopenia, neutropenia and 
thrombocytopenia), hypertension and an increased risk of venous and arterial thromboembolic 
events. Less common side effects were gastro-intestinal perforation, cerebral bleeding, fatigue and 
wound healing complications [24].  
The topoisomerase inhibitor, Irinotecan, prevents the DNA from unwinding and inhibits DNA 
replication and gene expression [25]. A stage II RCT compared concurrent radiation plus 
Bevacizumab and Irinotecan plus adjuvant Temozolomide (n=31) with concurrent radiation plus 
Bevacizumab and Temozolomide plus adjuvant Temozolomide (n=32) and found no difference in 
mean progression free survival (PFS) between the two arms [26]. A second stage II RCT did not find a 
statistically significant difference between the Stupp protocol (n=60) and a combination of 
Bevacizumab and Irinotecan followed by Radiation therapy and Temozolomide and adjuvant 
Bevacizumab (n=60)  [27]. A single arm stage II study by Vredenburgh and colleagues using a 
combination of Stupp protocol plus concurrent Bevacizumab followed by adjuvant Bevacizumab, 
Temozolomide and Irinotecan (n=75) reported a mean overall survival (OS) value of 21.2 months 
which falls within the range for mean OS values obtained for patients on the Stupp protocol (11.7-23 
months) [28].  
Other chemotherapy drugs that also did not confer a survival benefit when added to the Stupp 
protocol in single arm Stage II trials were the survival pathway inhibitors, Everolimus (mammalian 
target of rapamycin inhibitor) (n=68)[29], Gefitinib (tyrosine kinase inhibitor) (n=96 and 119) [30,31] 
and Erlotinib (tyrosine kinase inhibitor) (n=72 and 65) [32,33], the angiogenesis inhibitor, Enzastaurin 
(n=66) [34] and the radiosensitiser, Cis-retinoic acid (n=61 [35]). 
In summary, the addition of other chemotherapy agents, or changes in the Temozolomide dosing 
schedule does not seem to have increased patient survival. 
Hypo-fractionated radiation therapy as part of the Stupp protocol  
More than 85% of high grade gliomas recur within the high dose region indicating that 60Gy in 30-
fractions is not sufficient [9]. Recent improvements in diagnostic imaging, volume delineation and 
more conformal radiation delivery techniques have allowed for dose escalation (through increasing 
the dose per fraction: hypo-fractionation) to the tumour with the aim of improving survival without 
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increasing treatment morbidity. Several stage II single arm clinical trials have investigated the effect 
of using hypo-fractionated radiation therapy rather than conventional radiation therapy as part of 
the Stupp protocol. The advantage of hypo-fractionated (>2Gy per fraction) over conventional 
regimen (2Gy per fraction) is that the same dose can be delivered over a shorter period of time.  
Because a larger dose per fraction kills more tumour cells than 2Gy per fraction, the biologically 
equivalent dose (and thus efficacy) of 60Gy delivered in >2Gy fractions is larger than the same dose 
delivered in 2Gy fractions. The stage II single arm trials described in Table 1.2 have used a total dose 
of either 60Gy [36,37] or 68Gy [38,39] with a dose per fraction varying from 2.7Gy [37], 6Gy [36] and 
8.5Gy [38,39]. The mean overall survival of these studies was similar to that reported for the Stupp 
regimen [2,17–20,40]. Hypo-fractionation was well tolerated and had the added advantage of being 
delivered over a much shorter period of time, giving the patients more time with their family. While 
these stage II trials show promising results, stage III RCTs are required before hypo-fractionated 
radiation therapy in primary treatment will be implemented as standard practice.  
Table 1.2: The effect of hypo-fractionated RT as part of the Stupp regimen on patient 
outcomes. 
Primary Treatment: hypo-fractionated RT (Stage II single arm) 










60Gy in 10#  
over 2 weeks 
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16.6 (range 4.1-35.9) 
 
Jastaniyah 2013 [37] 
60Gy in 22#  
over 4.5 weeks 
25 6.7 (4.0-14.0) 15.7 (11.56-20.04) 60% 
Iuchi 2014 [38] 
68Gy in 8#  





Miwa 2014 [39] 
68Gy in 8#  
over 2 weeks 
45 13 (range 3-48) 20 (range 3-48) 53% 
Carlson 2014 [41] 
60Gy in 10#  
over 2 weeks 
26 9.4 16.3 84% 
No. of pts = number of patients, PFS = progression free survival, OS = overall survival, 6 m = 6 months, # = fraction 
1.4.2 Salvage treatment options 
Whilst the Stupp protocol provides a clear gold standard for newly diagnosed GBM patients, this is 
not the case for recurrent GBM. Because of the nature of the disease, the rarity of a complete 
resection combined with its resistance to radiation and chemotherapy, invariably, patients relapse. 
For some patients, disease progression becomes clear with the appearance of old or new 
neurological and/or cognitive symptoms; for others it is a follow-up MRI scan which shows 
progression of old lesions and/or the appearance of new lesions. Prognosis after disease progression 
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is very poor and many chemotherapy and radiation therapy regimes have been trialled in relapsed 
GBM patient cohorts to improve patient outcomes [1, 42, 43, 44, 45, 46, 47, 48, 49]. Because of the 
short life expectancy, treatments have focussed not only on extending life but also on maintaining 
quality of life.  
Salvage Surgery/Radiosurgery 
For some patients, surgical resection or radiosurgery is possible. This is only possible if the tumour is 
small and not adjacent to or infiltrating critical structures of the brain. Park and colleagues [42] 
devised a scale to predict patient survival after salvage surgery taking into account the location and 
volume of the lesions and Karnowski performance status. Patients with a good, moderate or poor 
prognosis were likely to live another 9.2, 6.3 and 1.9 months respectively [42]. These values are 
similar to those reported for radiosurgery [43]. When Cuneo and colleagues added Bevacizumab to 
radiosurgery they found a significant survival advantage of 11.2 months for the radiosurgery plus 
Bevacizumab arm over 3.9 months from salvage radiosurgery alone. They also found that patients 
with a good Karnovski status (>70) did better than those with poor status (11.9 and 1.9 months 
respectively) [43]. 
Salvage Hypo-fractionated Radiation Therapy 
Hypo-fractionated radiation therapy was shown to be at least as effective as conventionally 
fractionation radiation therapy in newly diagnosed GBM patients and has the added advantage of 
taking patients away from their daily life for a shorter period of time (usually only one to two weeks, 
compared with the six weeks necessary to complete the conventional treatment). Salvage hypo-
fractionated radiation therapy has been used for relapsed GBM patients in three stage II trials and 
six retrospective analyses with different dosage regimen (Table 1.3).  
The big challenge with irradiating parts of the brain for the second time is the cumulative nature of 
radiation damage. Previous doses must be considered in order to avoid over-dosing critical 
structures and to avoid radiation necrosis in normal brain tissue. Patients with brain tumours have 
MRI scans every three months to determine if the tumour is responding to treatment, remaining 
stable or progressing. MRI scans do not give any information about the biological activity of the 
tumour lesions and are therefore not able to distinguish between pseudo-progression (caused by 
post-treatment tissue changes that are not part of the disease process) and real disease progression.  
Miwa and colleagues fused MET-PET with CT and MRI scans to construct treatment plans and found 
that this combination was best at delineating target volume and sparing normal tissue, leading to a 
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low toxicity profile. They further showed that adding Temozolomide (200mg/kg/day for 5 days per 
month for at least 3 months) after hypo-fractionated radiation therapy (one week of daily 5 or 7Gy) 
doubled the mean overall survival to 20 months [39]. 
Table 1.3: The effect of salvage hypo-fractionated radiation therapy on patient outcomes. 
 Secondary treatment: hypo-fractionated RT 











Miwa 2014 [44]  
Stage II RCT  
 
1. 25-35Gy/5 or7Gy# 
MET-PET/CT/MRI 
8 5 6   






Grosu 2005 [45] 
Stage II RCT  
 
1. 30Gy in 6# of 5Gy in 6 
days MRI/CT  
    5 (3-7)   
2. Same as 1+MET-
PET/MRI/CT  
33   9 (3-15)   
3. Same as 2 plus TMZ     
11 (9-11) 
P=0.03 (1 and 
2) 
P=0.04 (2 and 
3) 
  
Gutin 2009 [46]  
Stage II single 
arm 
30Gy in 5# of 6Gy+ BEV 20 
7.3 (4.4-
8.9) 
12.5 (6.9-22.8) 65% 
Combs 2005 
[47] 
Retro analysis 36Gyin 2Gy#  32 
5 (range 
1-21) 
8 (range 1-205)   
Fogh 2010 [1] Retro analysis 
1.35Gy in 3.5Gy# 








Hasan 2015 [48] Retro analysis 
18-35Gy in 3-5# plus 
BEV/TMZ/anti-EGFR 




37.5Gy in 15# in 3 weeks 
conc TMZ 
35 5 9.7 42% 
Minniti 2013 
[50] 
Retro analysis 30Gy in 6Gy# conc TMZ 54 6 12.4   
Cuneo 2012 [43] Retro analysis  
1. Radiosurgery 16 2.1 3.9  22% 






No of pts = number of patients, PFS = progression free survival, OS = overall survivial, 6m = six months, RCT = randomised controlled 
trial, MET PET = methionine positron emission tomography, TMZ = Temozolomide, BEV = Bevacizumab, EGFT = epidermal growth factor 
receptor. Conc = concurrent  
 
Grosu and colleagues [45] also found that fusing MET-PET with MRI/CT scans for tumour volume 
delineation scans improved mean overall survival of patients compared with using MRI/CT scans (9 
and 5 months respectively). Similarly they found that adding Temozolomide (200mg/m2/day for 1-2 
cycles before and 4-5 cycles after hypo-fractionated radiation therapy) to the regime increased 
mean overall survival to 11 months from recurrence [45]. 
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Other combinations of hypo-fractionated RT with chemotherapy were explored. Gutin and 
colleagues [46] combined hypo-fractionated RT with Bevacizumab in a single arm study. They used 
MRI/CT scans for tumour delineation and reported a mean overall survival of 12.5 months.  
Six retrospective analyses reported on the effect of hypo-fractionated RT for recurrent GBM, two of 
these used hypo-fractionated RT without additional chemotherapy. Combs and colleagues [47] used 
a conventional fractionation regimen (36Gy in 2Gy per fraction) and reported a mean overall survival 
of 10 months. Fogh and colleagues [1] used a 35Gy in 10 fractions of 3.5Gy regimen, which is a lower 
dose per fraction than most other hypo-fractionated RT regimen (5-10Gy per fraction). All patients 
had hypo-fractionated RT alone or in addition to repeat craniotomy or concomitant chemotherapy. 
There was no significant benefit of surgical resection or chemotherapy in this population when 
analysis was controlled for other prognostic factors.  This trial found a mean overall survival of 11 
months [1]. 
Minniti and colleagues [49] conducted two retrospective studies using concurrent Temozolomide 
and re-irradiation. They reported a mean overall survival of 12.4 months for a 6Gy fraction regimen  
[50] and 9.7 months for a 2.5Gy fraction regimen. 
A combination of hypo-fractionated RT of 18-35Gy in 6-fractions with a combination of 
Bevacizumab, Temozolomide and an anti-EGFR inhibitor led to a mean overall survival of 5.3 months 
from the end of salvage therapy and 8 months from recurrence in a recent study conducted by 
Hasan and colleagues [48].  
Salvage Chemotherapy  
A large number of trials have used Temozolomide to treat relapsed GBM patients. Chen and 
colleagues performed a meta-analysis of 15 Stage II clinical trials [51]. They reported outcomes as 
the percentage of patients surviving for a number of months or years. They found an overall clinical 
benefit of using Temozolomide of 50.5% (95%CI 44.3-56.7%) with metronomic schedules and a high 
average dose (>100mg/m2) significantly better than standard Temozolomide dosing schedules 
(61.4% versus 46.3%; P=0.037). They reported a 6 month PFS of 22.7% (95%CI 22.7-33.5%), 6 month 
OS of 65% (95%CI 57.4-71.9%) and 12 month OS of 36.4% (95%CI:26.9-47.1) with no statistically 
significant difference between metronomic and high average dose schedules [51]. This compared 
well with other chemotherapy agents analysed in an older meta-analysis of Wong and colleagues 
which reported a clinical benefit of 33%, 6 month PFS of 15%, median PFS was 2.3 months and 
median overall  survival of 7 months [52]. 
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Several stage II studies evaluated  the effects of Bevacizumab [53–59], Irinotecan [60–65], Erlotinib 
[57,66–68], Thallidomide [69,70], Sirolimus [71], Etoposide [72,73], Hydroxyurea [74,75], Sorafinib 
[67,76], Carboplatin [72,73], Imatinib [74,75,77], Vandetanib [78], Bortezomib [79] and Vorinostat 
[79]. A summary of the mean overall survival of these studies shows that values fall between 3.2 and 
10.5 months, which are similar to those for surgery/radiosurgery and hypo-fractionated radiation 
therapy alone (Appendix B). Adding chemotherapy (Temozolomide or Bevacizumab) to hypo-
fractionated radiation therapy seems to have the best survival profile without increased toxicities. 
At Auckland Radiation Oncology (ARO) all patients are reviewed upon recurrence at a 
multidisciplinary meeting. The patient will have surgical resection of recurrent disease if possible, 
followed by hypo-fractionated radiation therapy following the Fogh [1] protocol or a reduced dose in 
patients where critical structures would otherwise be over-dosed. A retrospective analysis of this 
protocol in patients treated at ARO and Auckland City Hospital between 2009 and 2014 found similar 
overall survival results. A randomised phase II RTOG trial (RTOG 1205; is currently recruiting patients 
https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1205). The trial is 
randomising patients to Bevacizumab and re-irradiation (Fogh protocol) or Bevacizumab alone. The 
normal tissue dose limits used at ARO are from this RTOG 1205 protocol. After hypo-fractioned re-
irradiation, patients at ARO often have further chemotherapy with Temozolomide, Bevacuzumab 
and Irrinotecan, or Lomustine (CCNU). Depending on their response to chemotherapy and observed 
toxicity, patients may have several lines of salvage chemotherapy i.e. if they progress on 
Temozolomide or find it intolerable they may try Bevacizumab and Irinotecan.     
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1.5  Health-related quality of life  
Although HRQOL is now recognised as an important additional outcome to tumour response and 
overall survival, it is still not adequately addressed in most high grade glioma patients [80]. Although 
there are many options for collecting HRQOL data, many of these are not easily used or interpreted 
by clinicians (who are not usually experts in quality of life methodology). There is also a need for 
HRQOL data to be presented in a clinically meaningful way so that the pros and cons of new regimes 
can be weighed up in terms of increased survival and the impact on HRQOL [81]. 
HRQOL questionnaires 
Various health-related quality of life measures are available for use in brain tumour trials as well as 
in routine clinical work. One frequently used tool is the Functional Assessment of Cancer Therapy-
General (version 4) (FACT-G) questionnaire [4]. It consists of 27 items covering physical, 
social/family, emotional and functional wellbeing [82]. The generic questionnaire is accompanied by 
a brain cancer specific module consisting of a further 23 items that are relevant to patients with 
brain tumours [83]. This scale focusses on the psychosocial aspects of the disease. The MD Anderson 
Symptom Inventory (MDASI) questionnaire is a recently designed questionnaire that is specifically 
designed to measure the severity of symptoms in cancer patients as well as the effect of these 
symptoms on daily life [84].  
Another commonly used HRQOL questionnaire is the European Organisation for Research and 
Treatment of Cancer quality of life questionnaire core-30 (EORTC QLQ-C30, version 3). This 
questionnaire is more focused on functioning and symptoms but does assess the impact of cancer 
and its treatment on the physical, psychological, and social functioning of patients [85]. EORTC QLQ-
C30 consists of five function scales— physical, role (i.e., daily life), emotional, cognitive, and social; 
three symptom scales—fatigue, nausea and vomiting, and pain; six single-item scales—dyspnoea, 
insomnia, appetite loss, constipation, diarrhoea, and financial effect of tumour and treatment; and 
overall health and quality of life [81] (Appendix C). This questionnaire was developed with the 
intention of supplementing it with site specific questionnaires such as the brain cancer module 
EORTC QLQ-BN20 (Appendix D), which was developed and validated specifically for patients with 
brain cancer undergoing chemotherapy or radiation therapy. BN-20 has 20 items that assess issues 
such as visual disorders, motor dysfunction, communication deficit, various disease symptoms (e.g., 
headaches and seizures), toxic effects of treatment (e.g., hair loss), and future uncertainty [86]. 
EORTC QLQ-C30 and QLQ-BN20 have robust psychometric properties as a result of rigorous testing 
in several international clinical trials [87]. The large Stupp trial [2] used these EORTC questionnaires 
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to evaluate the impact of the addition of Temozolomide chemotherapy to treatment on HRQOL. This 
trial found the questionnaires to be practical to use and provided useful HRQOL information that 
informed the decision to add Temozomide to the standard treatment protocol [88].   
The QLQ-BN20 questionnaire was validated using 105 patients and identified differences in the 
responses between patients with recently diagnosed and recurrent cancer and between patients 
with a Karnofsky Performance Score (KPS) of 50-70 and 80-100. These differences were in the 
expected direction, indicating that the module of questions is responsive to a variety of conditions 
that patients with the disease can experience. Patients with either mental confusion, motor deficit 
or dysphasia scored high in several domains and single items compared with patients without these 
neurological deficits. Thus, differences in the responses to the items in the brain cancer module 
appear to reflect differences in neurological status. In addition, deteriorating neurological status was 
accompanied by a marked increase in emotional distress, future uncertainty and motor dysfunction. 
In order to check consistency of answers patients were tested then asked to recomplete the 
questionnaires less than seven days later. The answers showed good consistency between 
responses. Areas where there were inconsistencies were generally explainable by a change in 
condition rather than random deviations for instance when the patient had started radiation and 
was experiencing itchy skin [86].  
As HRQOL is increasingly being used as an outcome measure in clinical trials it is important to 
evaluate the clinical meaningfulness of changes in HRQOL. A statistically significant difference in 
HRQOL may not translate into a clinically meaningful change and vice versa. For instance, in a large 
trial statistical significance is more likely to be achieved but may still not be clinically significant for 
the patient or the clinician [89]. Maringnwa and colleagues [89] conducted a trial in order to better 
determine the minimal clinically important difference in HRQOL scores for patients with brain cancer 
using the EORTC QOQ-C30 and BN-20. Although the correlations to the anchoring tests, such as a 
decrease in KPS score, did not necessarily correlate perfectly with a decrease in overall quality of life, 
there was a reasonable correlation overall. This study found that a small 5-10% change in HRQOL 
scores was clinically meaningful [89]. The original validation work for EORTC BN-20 showed that a 
change in score of ≥10 points on any given scale could be interpreted as being clinically meaningful 





1.6  Aim and Objectives  
The previous sections have highlighted that the current best standard of treatment for high grade 
gliomas results in an average overall survival of 15-20 months. Eventually patients relapse and need 
salvage treatment such as hypo-fractionated radiation therapy. Individuals cope differently with the 
various aspects of a cancer diagnosis and treatment, partly depending on their inborn resilience but 
also depending on their personal circumstances. The cancer journey for each recurrent high grade 
glioma patient is unique. Disease and treatment symptoms in this cohort depend to a large extent 
on the location, extent and treatment of previous disease and the treatment and the location of 
recurrent lesions.  
This thesis aims to describe the journey of seven high grade glioma patients through their salvage 
radiation treatment and the period immediately after completion of treatment. 
 
The specific objectives that address the aim are: 
1. To measure HRQOL parameters and changes in these parameters before, during and after 
completion of hypo-fractioned re-irradiation. 
2. To determine the nature and severity of tumour-associated symptoms before, during and 











Chapter 2   Methodology 
Having established the aim of this project to be “describing the journey of a number of high grade 
glioma patients through salvage radiation therapy”, a prospective observational cohort study design 
was deemed most appropriate. This longitudinal study follows a group of seven high grade glioma 
patients through their salvage radiation therapy and the period immediately after this, describing 
their salvage treatment, side effects from the disease and the treatment and the effects of these on 
daily life. The following sections will describe the study context, ethical approval, funding, measures 
and a description of the cohort, as well as data sourcing and analysis.  
2.1  Context 
This study was carried out to fulfil the research requirements of the postgraduate honours degree in 
Radiation Therapy, the BRT (honours). The author of the thesis has been a full time staff radiation 
therapist at Auckland Radiation Oncology since 2011; she was also the research radiation therapist 
responsible for patient recruitment, administration of the questionnaires and data analysis. The 
requirement for this 90 point honours thesis is to conduct a piece of primary research part time over 
two years; data collection for this thesis took place from September 2014 until December 2015. 
2.2  Ethical Approval  
This study was approved by the Otago University Human Ethics committee on 11th August 2014, 
protocol number H14/091. A variation was accepted for the inclusion of recurrent anaplastic 
astrocytoma (WHO grade III) (AA) in June 2015. All patients gave written informed consent before 
being entered into the study. 
2.3  Funding  
The salary of the primary supervisor, Dr Patries Herst, was paid by the University of Otago. The 
salary of the author, Jenny Knight, was paid by Auckland Radiation Oncology Ltd. The Auckland 




2.4.  Participants  
Participant inclusion criteria  
Eligible patients needed to have histologically confirmed GBM and radiologically confirmed 
recurrence. At the time of original diagnosis, the patient must have received maximal surgical 
resection, radiation therapy and Temozolomide chemotherapy. Patients must be aged >18 years old 
and have a Karnosky performance score of >60 (Appendix E). Due to slow patient recruitment by 
June 2015 the inclusion criteria were extended to include patients with recurrent AA after this 
amendment was approved by the ethics committee.  
Participant numbers 
Because of the time constraints imposed by the BRT (honours) programme and in order to capture 
the experience of a range of patients, all patients receiving salvage irradiation for recurrent GBM 
(and later AA) between September 2014 and August 2015 were approached to participate in this 
study. A total of seven patients were recruited for this study. Data collection continued until 
December 2015. 
Patient flow through the study 
In the 12 months following ethics approval 13 eligible patients were treated at Auckland Radiation 
Oncology, 12 relapsed GBM patients, and one relapsed AA patient.  
One potentially eligible patient was not approached because of violent tendencies noted in his 
referral letter. Another patient was not approached because she was very anxious and in denial of 
her condition; it was deemed likely that talking to the patient about the trial would cause her undue 
distress. One patient was “missed” due to the author being away for the first two fractions of 
treatment. Of the 11 patients who were approached about the study, two patients declined 
participation due to high levels of fatigue and one patient declined participation citing difficulties 
communicating as he did not speak English. Baseline scores of one patient were missed. A total of 
seven patients participated in the study.  
Data collection ceased for all patients in December 2015 in order to allow for data analysis, allowing 
a minimum of 5-months follow-up time for all patients. The flow of patients through the study is 
shown in Figure 2.1.  
21 
 




2.5  Measures 
2.5.1. Quality of Life Questionnaires  
Participants were asked to fill out two HRQOL questionnaires on day one of radiation treatment, 
mid-way through radiation treatment, on their final day of radiation treatment and at all subsequent 
routine follow-up appointments with their Radiation Oncologist. The first of these questionnaires 
was the EORTC QLQ-C30 (appendix C). This tool assesses patients’ general HRQOL and has been 
validated in several clinical trials in Europe and USA [85]. While this questionnaire enables 
comparisons to be made across cancer patient populations, it does not provide adequate data about 
disease specific symptoms and treatment side-effects experienced by patients with brain tumours. 
Therefore, patients also filled in the more specific EORTC QLQ-BN20 (Appendix D). This 
questionnaire was specifically designed for brain cancer patients and has also been validated by 
large international trials [86,91]. Patients fill in the EORTC QLQ-C30 and QLQ-BN20 questionnaires 
themselves, scoring items on a 4-point response scale, ranging from “not at all” to “very much” with 
higher scores indicating more impairment. The exceptions are the “global health” and “overall 
quality of life” items of the QLQ-C30 that are scored on a 7-point Likert scale, ranging from “very 
poor” to “excellent” where higher scores indicated a better HRQOL. QLQ-C30 and B20 scores for this 
project were not converted onto a linear scale and simply left as ‘not at all’ ‘a little’ ‘quite a bit’ and 
‘very much’ for reporting. A change between each category represents a 25% change in HRQOL on 
scales where there are only four categories; therefore, a change in category correlates to a clinically 
significant change.  
2.5.2. Treatment side effects  
Clinical trials reporting on the toxicity of cancer treatments use validated scales such as the Common 
Terminology Criteria for Adverse Events (CTCAE) from the National Cancer Institute of America 
(http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14). The intent was to use CTCAE to score 
the side effects from re-irradiation at various time points for each of the patients. This information 
would be expanded on by conversations with the patients about their symptoms and how these 
affected their day-to-day life. Because of the very short life expectancy of these patients it was 
decided that the author would not conduct separate interviews about their side effects as additional 
visits would increase the burden on these very vulnerable patients unnecessarily. Instead, the author 
attended radiation therapy treatment appointments and patient consultations with the radiation 
oncologist (with the patients’ permission) and took notes of the conversations between the 
radiation therapists or oncologist and the patients about their side effects and their day-to-day life. 
For the first patient, the author went through the CTCAE questionnaire after the oncologist had 
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talked to the patient at the end of the consultation. However, the patient found it repetitive as many 
of the questions of the CTCAE questionnaire had already been answered, and it made the 
consultation very long. Therefore, the CTCAE questionnaire was not used for any of the other 
patients. The author made careful note of the side effects as expressed by the patients and these are 
reflected in the patient journey described in the results section. The author cross referenced her 
observations with notes from the treatment radiation therapists and radiation oncologist in the 
patient file. 
2.5.3. Review of patient notes 
 A review of patient notes was done to obtain information about the date of original diagnosis, 
presenting symptoms, first line therapy, time to relapse and any other salvage therapies that the 
patient may have had. The patients’ treatment plan was also reviewed in the RayStationTM treatment 
planning system to determine the size of target and doses to critical structures. Diagnostic imaging 
(i.e. PET and MRI scans) and reports were also reviewed to gain an insight into radiological response 
of the tumour.  
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2.6 Study Timeline 
 
Figure 2.2 Study time line 
The study time line is depicted in Figure 2.1. The study was first mentioned to the patient by their 
radiation oncologist at their first meeting to discuss salvage treatment. The author then discussed 
the study with each patient at the time of their RT planning CT session and explained the aim of the 
study and what their participation would involve. The patient information sheet (Appendix F) and 
informed consent sheet (Appendix G) were also given to the patient at their planning CT. The timing 
between meeting with the oncologist and treatment commencement varies due to a number of 
clinical and logistical factors however treatment is always commenced as soon as possible. 
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Between the planning CT and treatment commencement there was at least one week to allow for 
the planning of treatment. This period gave the patients and their families an opportunity to read 
the information in the information sheet and consider if they wanted to participate. The patient 
information sheet provided contact numbers for the author so that patients were able to contact her 
by phone if they had any questions.  
On the first day of treatment, if patients consented to participate in the study, they signed the 
informed consent form which was filed in the patient notes. The patient completed both baseline 
EORTC questionnaires. These EORTC questionnaires were repeated midway through treatment and 
on their final day. The author scored any radiation therapy related side effects according to the 
CTCAE scoring toll for the first patient and generally built rapport with the patients and gained an 
insight into their treatment experience and daily life on at least two occasions during treatment.  
The follow-up pattern for patients varied largely according to their needs. They were generally 
reviewed two weeks post radiation treatment when side effects are thought to be at their peak. 
They were then reviewed 6 weeks post treatment when most side effects had resolved. At this time 
further therapy such as chemotherapy was discussed. An MRI was performed three months post 
treatment to assess the tumour response to treatment. Further follow-up was on a bimonthly basis 
with repeat MRIs at regular intervals. Follow-up visits were more frequent in patients whose 
condition changed and required intervention or monitoring more closely. Fewer follow-up visits 
were done with patients who were doing well or were under the care of a medical oncologist due to 




2.7 Data collection and analysis  
Information regarding the salvage treatment journey of individual patients in this study has been 
provided in the form of case reports that describe the effects of treatment on health and other 
aspects of each patient’s life. Each case report contains a brief description of the disease and 
treatment history, current treatment and HRQOL data from the questionnaires, and data regarding 
the side effects and notes taken during sessions with the radiation oncologist. Because each patient 
is likely to suffer different side effects of the tumour as well as treatment due to differences in 
location, number of lesions, comorbidities etc. (see section 1.2), the author decided to focus on 
elements from these questionnaires where the patient reported scores of ‘quite a bit’ and ‘very 
much’ at any time during their study participation. Scores of ‘not at all’ and ‘a little’ were not 
reported in order to simplify results and to focus on areas that were of concern to each individual 
patient. Scores for ‘global health’ and ‘overall quality of life’ were also reported as the author felt 
that they gave a meaningful overview of how all of these elements added to their view of health and 
overall quality of life. 
 No attempt is made to compare or statistically analyse data between patients as this purely 
observational study aimed only to document the treatment journey of recurrent high grade glioma 
patients treated at ARO between September 2014 and December 2015. Because data collection 
occurred during a defined period of time, patients enrolled early in the study were followed up for 
longer than patients recruited towards the end of the study recruitment period.  
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Chapter 3   Results  
This chapter describes the details of disease progression, treatment and quality of life of the seven 
patients in this study. A table with demographic information will be followed by specific patient 
characteristics, a description of primary and salvage treatments as well as the relevant treatment 
plans. The final section consists of a description of the patient journey through and after salvage 
treatment and a section on patient specific changes in HRQOL, based on the EORTC QLQ-C30 and 
EORTC QLQ-BN20 questionnaires. 
3.1. Patient GBM01  
Table 3.1.1: Demographic characteristics of patient GBM01. 
Patient Identifier  GBM01 
Gender and Age Female, 50yrs old 
Karnovski score (at recurrence) 70% 
Tumour grade (initial)  GBM WHO grade 4 
Tumour location  Right & Left Frontal  
Date of initial diagnosis 30/12/2009 
Start of primary treatment January 2010 
Date of recurrence August 2014 
Time to recurrence 4 years 8 months 
Type of recurrence Clinical progression  
Start of salvage treatment September 2014 
Survival from salvage treatment  15 months 
Status at  Dec 2015 Alive 
Patient Characteristics 
The patient is a 50 year old female who is married without children. At the time of diagnosis, she 
was working part time as a zoo keeper and part time at an eye clinic. After her initial diagnosis the 
patient ceased working. She and her husband lived on the North Shore of Auckland throughout her 
primary treatment. In the time between her primary treatment and secondary treatment the patient 
and her husband moved to Taupo where they purchased a lifestyle block.   
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Presentation and Primary treatment 
GBM01 presented to North Shore hospital in December 2009 with a history of two tonic-clonic 
seizures. CT demonstrated an abnormal area in the right frontal lobe.  The CT was followed by an 
MRI which also found an area of abnormality in the superior frontal lobe measuring 7.5cm which 
extended across midline by at least 3 cm. Debulking surgery was performed, histology confirmed 
GBM WHO grade 4 possibly arising from a lower grade tumour with oligodendroglioma-like features. 
Surgery was followed by Radiation Therapy and adjuvant Temozolomide chemotherapy. 3D-
conformal radiation therapy of 59.4Gy was delivered in 33 fractions, 1.8Gy per fraction, one fraction 
per day, five fractions per week, over 7 weeks (see Figure 3.1.1 and table 3.1.2. for treatment plan 
and dose distribution details). Concurrent Temozolomide 100mg daily for 42 days was administered. 
This was meant to be followed by adjuvant Temozolomide of 300mg for 5 days of each month for 6 
months however this course could not be completed due to low platelet counts (thrombocytopenia).  
 
 
Figure 3.1.1: Primary Radiation Therapy Treatment Plan.  
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Table 3.1.2: Dose to critical structures from primary radiation treatment for GBM01 
Structure  Dose  Volume 
Brain (incl. PTV) 60Gy 280 cm
3
 (24% of whole brain volume) 
Brainstem 55.6Gy  0.1cm
3
 




After completing primary therapy, GBM01 had regular MRIs and remained well on clinical 
examination for four years. In February 2014 a follow-up scan showed stable disease with no 
features to suggest disease progression. In August 2014 GBM01 experienced headaches, difficulty 
with speech and some loss of voluntary control over movement over a two-week period. An MRI 
scan correlated this clinical decline to significant tumour progression. The anti-inflammatory 
corticosteroid, Dexamethasone, was prescribed to reduce intracranial pressure and minimise the 
acute symptoms of the tumour recurrence. A significant reduction in symptoms was achieved five 
days after the patient started taking Dexamethasone.   
Salvage Treatment  
Salvage treatment consisted of re-irradiation with 35Gy in 10 fractions, 3.5Gy per fraction, 1 fraction 
per day, 5 fractions per week over two weeks. In RayStationTM a deformable image registration was 
performed in order to assess cumulative doses to critical areas in the brain. Due to doses to critical 
structures received previously, parts of the volume were treated to a reduced prescription of 30Gy 
in 10-fractions (see Figure 3.1.2 and Table 3.1.3 for cumulative dose distribution details from course 
one and course two). Concurrent Temozolomide of 100mg daily during treatment was prescribed. 
Adjuvant Temozolomide of 300mg for 5 days of each month for 6 months was prescribed following 
re-irradiation.  
 
Table 3.1.3 Composite dose to critical structures from Primary & Secondary Radiation 
therapy for GBM01 
Structure  Dose  Volume 
Brainstem 2.46Gy  0.1cm3 
Optic chiasm 1.77Gy  0.1cm3 
Brain cumulative  60Gy 40% 
Brainstem (cumulative EQD2) 57.9Gy ± 1.6Gy 0.1cm3 
Optic chiasm (cumulativeEQD2) 53.8Gy ± 1.6Gy 0.1cm3 




Figure 3.1.2: Composite of Primary & Secondary Radiation Therapy Plans for GBM01  
Patient Journey through Salvage Treatment   
This section describes the journey at different time points through salvage treatment. Figures 3.1.3 
and 3.1.4 at the end of the section are graphs of the EORTC questionnaire responses.  
During treatment  
The patient continued on Dexamethasone and anticonvulsants throughout re-irradiation treatment. 
Throughout re-irradiation the patient’s overall health and overall QOL scores remained ‘excellent’. 
Fatigue scores increased from ‘not at all’ to ‘a little’. Halfway through treatment the patient was ‘a 
little’ concerned about disruption to family (Figure 3.1.4). This may have been caused by the fact 
that the patient was treated in Auckland for treatment while living in Taupo. Over the course of 
treatment however her coordination and feeling steady on her feet improved. The patient also 
reported difficulty sleeping, which resolved when she stopped taking Dexamethasone. 
Six weeks post re-irradiation  
The patient believes that treatment has been a success as she is off Dexamethasone and reports 
feeling well. However, she self-referred to the hospice as she wanted to know what the future could 
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hold in general terms as she is aware that her tumour is incurable. It is also at this time point that 
her ‘severity of symptoms scores’ were at their worst.  
Three months post re-irradiation 
The three-month follow-up MRI scan showed a significant treatment response following this phase 
of treatment; Temozolomide chemotherapy was continued.     
Four months post re-irradiation 
The patient had recovered markedly from the time of recurrence prior to salvage radiation therapy 
with no headaches or confusion.  Her verbal fluency had returned to normal and she was going 
about her daily activities without any significant problems. This correlated well with decreased 
severity of symptoms scores and overall health score improving. 
Five months post re-irradiation 
The five month MRI showed stable disease over the past three months. Adjuvant Temozolomide was 
discontinued at this point due to thrombocytopenia. The chemotherapy regime was changed to 
Bevacizumab and Irinotecan as these drugs carry a reduced risk of thrombocytopenia. Bevacizumab 
and Irinotecan doublet therapy was prescribed for 8 to 10 cycles with one cycle every fortnight. The 
first two cycles were tolerated well with some nausea, controlled by anti-emetics, and mild fatigue.   
Six months post re-irradiation 
After two cycles of Bevacizumab and Irinotecan the MRI showed a significant reduction in the bi-
frontal masses. This correlated to a self-reported clinical improvement in the patient. EORTC severity 
of symptoms scores correlated with the patient continuing to feel a little tired and unsteady on her 
feet.   
Eight months post re-irradiation 
The eight month MRI showed continued response to Bevacizumab and Irinotecan. The 
chemotherapy continues to be well tolerated with nausea on the day of chemotherapy on the drive 
home to Taupo and continued fatigue. An increase in symptom score for unsteady on feet was 
reported this month. At this follow-up time, the patient described taking her donkey for a walk in 
the forest and nearly falling.   
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Ten months post re-irradiation 
The ten month MRI showed continued response. 10-cycles of double therapy of Bevacizumab and 
Irinotecan had now been completed and the patient was to continue with Bevacizumab alone. 
Symptoms of being a little tired, unsteady on her feet and problems with coordination continue. 
Eleven months post re-irradiation 
Despite the continued response of the patient’s previous MRI she showed deterioration at her next 
medical oncology appointment. She had a seizure a few weeks ago and had been falling recently. 
She had an unsteady gait. Physiotherapy and occupational therapy review were recommended. It 
was decided to continue with the next round of therapy and have a repeat MRI and FET-PET scan 
prior to the next round of therapy.  
Twelve months post re-irradiation 
The patient’s MRI and FET-PET scans demonstrated continued response to therapy. Her gait had 
improved a little and she had been falling less often. The plan was to continue with single agent 
Bevacizumab for a further three cycles.  
Thirteen months post re-irradiation 
Symptomatically the patient remained much the same. Her mobility remained an issue, neither 
deteriorating nor improving. A discussion was had around the impact that her mobility was having 
on her quality of life and ways of adjusting to what is likely to be her “new normal” and setting goals 
and adjusting her lifestyle accordingly. As the patients scan did not show progression it is suspected 
that the deterioration was a result of either late radiation therapy effects or chemotherapy toxicity.  
Fourteen months post re-irradiation 
The most recent MRI showed signs of progression. The patient was offered to retrial Irinotecan as 
she has now had a five month break from it or to trial Lomustine chemotherapy which she has not 
had yet or to discontinue active treatment and move towards supportive care and advanced 









Quality of Life  
The overall health and quality of life scores and important issues for this patient are shown in Figures 
3.1.3 and 3.1.4 respectively. Over the past year since re-irradiation with maintenance chemotherapy 
(Temozolomide followed by Bevacizumab and Irinotecan) patient GBM01 has shown a radiological 
response to therapy and importantly this was correlated with low ‘severity of symptom scores’. 
Overall health and quality of life have remained almost excellent despite ongoing therapy, although 
recently these have been trending down. Most of the toxicities of chemotherapy resolved within one 
day of stopping administration. At follow-up sessions the patient and her husband often told stories 
of their daily life on their lifestyle block. Although some symptoms affected the ability to do some 
things, mostly they had managed to adapt their lifestyle so that they could enjoy the time that they 
had together. For instance, the patient used to keep horses, however, now she has just one 
miniature horse because she found that she was scared of being knocked over by the larger animals. 
Since re-irradiation the patient has reported being ‘a little uncertain about the future’. Although she 
does well on a day-to-day basis she and her husband are realistic about her having an incurable 
brain tumour. Six weeks after salvage radiation when the patient’s symptoms were at their worst, 
the patient and her mother met with a nurse from the Hospice. The patient found discussions with 
hospice personnel were helpful and informative with respect to what to expect towards the end of 
life. However, as tumour symptoms and side effects of salvage radiation therapy resolved the 
patient did not have further contact with the hospice. At her follow-up in August 2015 (12-months 
after salvage radiation) with Medical Oncology, when she was showing clinical deterioration, 
advanced care planning towards the end of life was discussed. The patient’s condition remained 
stable over the next couple of months however in November 2015 her MRI showed signs of disease 
progression. The patient has been offered further salvage therapy however she is currently weighing 




Figure 3.1.3: Overall Health and Quality of Life scores for patient GBM01  
 
 




3.2  Patient GBM02  
Table 3.2.1: Demographic characteristics of patient GBM02. 
Patient Identifier  GBM02 
Gender and Age Female, 83yrs old 
Karnovski score (at recurrence) 70% 
Tumour grade (initial)  GBM WHO grade 4 
Tumour location  Right Parietal Lobe 
Date of initial diagnosis December 2013 
Start of primary treatment April 2014 
Date of recurrence January 2015 
Type progression Radiological  
Time to recurrence 8 months  
Start of salvage treatment February 2015 
Survival from salvage treatment 7 months  
Status at Dec 2015 Deceased 12 August 2015 
 
Patient Characteristics 
The patient was an 83 year old female; she was married and lived with her husband on their dairy 
farm in the Waikato. She and her husband were mostly retired with workers running the farm. She 
had three adult children and grandchildren. She enjoyed an active social life with her family and 
friends.   
Presentation and Primary treatment 
This patient presented with left facial droop, slurred speech, and left facial twitch, likely a partial 
seizure, in March 2014. In December 2013 the patient had been diagnosed as having a stroke. 
However, four months later she was diagnosed with a confirmed primary brain tumour. It is likely 
that the presentation of a stroke was actually the tumour’s first presentation. The patient started on 
Epilim and has had no further seizures. CT scan and MRI confirmed an abnormal area in the right 
parietal lobe measuring 52mm x 33mm x 45mm. There was a local mass effect (distortion of 
surrounding brain tissue due to tumour) with some surrounding oedema. A neurosurgical referral 
was made; however, surgery was not performed. Upon review of the MRI the neurosurgeon 
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believed that the patient had an astrocytoma which showed subtle signs of transformation from low 
to high grade. Given the patient’s age it is rare to have a truly low grade astrocytoma and this is 
more likely a high grade tumour. It was felt that total resection would be inappropriate given the 
patient’s age and a biopsy may be misleading as the tumour was likely to have some low grade and 
some high grade elements. 
In April 2014 primary radiation therapy of 60Gy in 30 fractions, 2Gy per fraction, 1 fraction per day, 5 
fractions per week over 6 weeks was prescribed (Figure 3.2.1). Radiation treatment was delivered 
using volumetric arc modulated therapy (VMAT). Concurrent Temozolomide of 80mg was 
prescribed; this is a lower dose than usual (200mg) due to the patient’s age. Chemoradiotherapy was 
tolerated extremely well and the patient experienced good resolution of tumour symptoms. She was 
no longer troubled by difficulties with speech (aphasia) and had no significant facial twitching or 
altered sensation. She proceeded to the adjuvant phase of Temozolomide chemotherapy at a dose 
of 200mg for five days each month for six months. The patient suffered no significant side effects 
from the TMZ, blood counts remained within normal range, and her quality of life was reported as 
excellent by her radiation oncologist.   
 





Table 3.2.2: Dose to critical structures from primary radiation treatment for GBM02  
Structure  Dose  Volume 
Brain (incl. PTV) 60Gy 93.1cc (7% of whole brain volume 
Brainstem 47Gy  0.1cm
3
 
Optic chiasm 34Gy  0.1cm
3
 
In September 2014 an MRI somewhat surprisingly showed possible tumour progression or 
pseudoprogression. As the patient was clinically better and not on steroids chemotherapy was 
continued and a repeat scan was recommended after two months.  
In November 2014 the patient collapsed (unwitnessed) and experienced prolonged loss of 
consciousness. A repeat MRI was performed and compared to the September 2014 MRI (Figure 
3.2.2). The appearances suggested a response to treatment, with less enhancement and mass effect. 
Following this the patient was admitted to hospital due to significant deterioration cognitively and 
physically. At this stage it was identified that she had a urinary tract infection which was likely to 
have been responsible for the collapse.  
 
 
Figure 3.2.2: Response to Primary Treatment on MRI for patient GBM02 
The patient proceeded with her final cycle of adjuvant therapy two weeks after the symptoms of her 
urinary tract infection had resolved.  
In January 2015 a repeat MRI showed areas of progression and areas of stable disease compared 
with the most recent CT scan in November 2014. A slight mass effect was reported with a 4mm 
midline shift.   
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Salvage Treatment  
Due to the progression in February 2015 the patient underwent re-irradiation. 35Gy in 10 fractions, 
3.5Gy per fraction, 5 fractions per week, over two weeks was prescribed (Figure 3.2.3). 
Chemotherapy was not administered concurrently. Adjuvant chemotherapy two months post 
radiation was to be considered.   
 
Figure 3.2.3: Composite Primary and Secondary Radiation Therapy Treatment Plans for GBM02  
Table 3.2.3: Composite dose to critical structures from Primary & Secondary Radiation 
therapy for GBM02. 
Structure  Dose  Volume 
Brainstem (PRV) 13.5Gy  0.1cm3 
Optic chiasm (PRV) 6.1Gy  0.1cm3 
Brain cumulative  60Gy 14.5% 
Brainstem PRV (cumulative EQD2) 52.9Gy 0.1cm3 
Optic chiasm (cumulativeEQD2) 38.2Gy 0.1cm3 





Patient Journey through Salvage Treatment   
During treatment 
The patient and her husband stayed in Auckland during the two-week period of re-irradiation. Over 
the course of treatment her functional scores such as ‘coordination’ and ‘feeling unsteady’ 
deteriorated. She also found that her need to rest increased from ‘not at all’ to ‘quite a bit’. During 
the latter part of treatment, the patient reported her lowest overall health and quality of life scores.  
Two weeks post salvage RT 
After two weeks of recovery post re-irradiation, functional scores largely remained unchanged 
however the patient’s overall quality of life improved significantly to almost excellent. This may be in 
part explained by being back at home and in her own environment and feeling like life was returning 
to normal.  
Six weeks post salvage RT 
The consultant radiation oncologist reported that she tolerated re-irradiation well with no significant 
nausea or headaches and was not on steroids. The patient had largely regained her mobility and was 
cooking again. She was also feeling less tired and her need for rest had diminished. Her overall 
health score also improved over the past four weeks.   
Three months post RT 
A repeat MRI showed partial response. Chemotherapy of oral Etoposide with a dose of 50mgs daily 
for two weeks of each month was prescribed. In consultation with the patient and her family there 
the tolerance for stopping chemotherapy would be low, because although there was residual 
disease, clinically the patient was well. The aim of the chemotherapy was to maintain this level of 
functioning for as long as possible but should not be at the expense of quality of life. The patients’ 
functional scores were largely similar to 6 weeks previously. Self-reported overall health and quality 
of life dropped by one point (see Figure 3.2.4). 
Four months post salvage RT  
Chemotherapy was initially well tolerated, however, the patient became tired and quite forgetful. As 




Five months post salvage RT  
Patient attended follow-up in a significantly worsened clinical condition. She was drowsy and ill 
coordinated. She was admitted to Auckland hospital. Initially it was suspected that her deterioration 
was due to progression of her brain tumour. A repeat MRI scan was performed and this did not show 
progression. During her stay at Auckland hospital she was diagnosed with a severe urinary tract 
infection and she was dehydrated. This resulted in significant levels of fatigue and confusion. With 
antibiotics and rehydration she improved significantly. 
Six months post salvage RT  
Since the resolution of the patient’s urinary tract infection she was improving. She had been back on 
Dexamethasone and it was felt by her Radiation Oncologist that this was causing some peripheral 
weakness. Although the patient had improved over the past month, there was a significant 
deterioration in her overall condition. During the follow-up consultation the patient often lost 
concentration and would change the topic of conversation mid-sentence. Her husband also reported 
that she was sleeping poorly at night and would often try and get up and start doing things in the 
night. She could be reasoned with and would go back to bed and settle for another few hours. At this 
follow-up almost all of the functional scores were at their worst. However, the patient still rated her 
overall quality of life and health as good.  
Two weeks after this follow-up visit the patient was admitted to Thames hospital and died peacefully 
of an infection within 30 minutes of being admitted to hospital.  
Quality of Life 
The overall health and quality of life scores and important issues for this patient are shown in Figures 
3.2.4, 3.2.5 and 3.2.6. Overall, patient GBM02 experienced a good response to re-irradiation 
treatment. Over the two week course of re-irradiation she reported some of her lowest overall 
health and quality of life scores and reported higher severity of symptoms scores. However, her 
overall health and quality of life scores recovered after finishing treatment and were mostly higher 
than pre-salvage therapy levels. Her severity of symptoms scores remained largely stable for a 
period after treatment, this correlated well with a partial response followed by stable disease on 
MRI. Although her survival was limited post re-irradiation, salvage treatment gave her and her family 
time to adjust to the prognosis and she made use of the opportunity of seeing family and friends 




Figure 3.2.4: Overall Health and Quality of Life Scores for Patient GBM02. 
 
 









3.3  Patient GBM03  
Table 3.3.1: Demographic characteristics of patient GBM03. 
Patient Identifier  GBM03 
Gender and Age F 69yrs old 
Karnovski score (at recurrence) 80 
Tumour grade (initial)  Glioblastoma w. Oligodendroglioma component   
Tumour location  Left Temporal  
Date of initial diagnosis 22/1/2014 
Start of primary treatment 13/03/2014 total surgical resection  
Date of recurrence 22/01/2015 
Time to recurrence 10 months  
Type of progression  Radiological 
Start of salvage treatment 10/2/2015 
Survival from salvage treatment  10 months  
Status at Dec 2015 Alive  
 
Patient Characteristics 
This patient is a trained nurse who worked in theatre. Later in life she went into car sales and held 
various executive positions. She is involved in charities that support young women to achieve 
professionally. She enjoys gardening and was a keen golfer. She lives on a lifestyle block with her 
husband. The patient’s husband came into the radiation therapy department with her however 
declined to come into the follow-up consultations with her.  
Presentation and Primary treatment 
The patient presented to her general practitioner with a two-month history of difficulties with 
speaking and understanding words. She also had a decreased sense of taste and a vague 
unsteadiness. An MRI confirmed a mass in the left temporal lobe that had appearances consistent 
with a primary glioma. The patient proceeded to surgery where gross total resection was performed. 
Histology confirmed GBM. The patient made a good recovery from surgery and had no new deficits.  
Radiation Therapy with concurrent and adjuvant Temozolomide chemotherapy was prescribed. 
Radiation therapy of 60Gy in 30 fractions, 2Gy per fraction, 1 fraction per day, 5 fractions per week 
over 6 weeks was delivered. This was followed by six months of Temozolomide chemotherapy of 




Figure 3.3.1: Primary Radiation Therapy Treatment Plan for GBM03. 
Table 3.3.2: Dose Distribution Details from Primary Radiation Treatment for patient 
GBM03. 
Structure  Dose  Volume 
Brain (incl. PTV) 60Gy 93.8 cm
3
 (6.8% of whole brain volume) 
Brainstem 55.1Gy  0.1cm
3
 




MRI was performed bimonthly to monitor for asymptomatic disease progression (Figure 3.3.2). This 
showed a partial response to therapy with stable disease for ten months. After first line treatment 
the patient was active in multiple administrative roles, however could not garden as much as she 
would have liked due to fatigue. She continued to improve over time and had been exercising on her 





Figure 3.3.2: Serial MRI images demonstrating stable appearances of tumour for patient GBM03 
Salvage Treatment  
In January 2015 the patient remained well clinically, however the MRI showed progressive disease. 
In February 2015 the patient had surgical resection of the area of enhancement. MRI post 
operatively showed that most, but not all of the enhancing material was resected. In March 2015 the 
patient had a second course of radiation therapy. 35Gy in 10 fractions, 3.5Gy per fraction, 1 fraction 
per day over two weeks was prescribed (Figure 3.3.3). Coverage of the target volumes was 
compromised to ensure that the brainstem and optic chiasm was kept within acceptable limits. 
Adjuvant Temozolomide was also prescribed; 300mg Temozolomide daily for five days of each 
month for six months.  
 
Table 3.3.3: Composite dose to critical structures from Primary & Secondary Radiation 
therapy for GBM03.  
Structure  Dose  Volume 
Brainstem +0.3cm 19.7Gy  0.1cm3 
Optic chiasm +0.3cm 13.1Gy  0.1cm3 
Brain cumulative (incl. PTVs) 60Gy 183cm
3
 13.25% 
Brainstem (cumulative EQD2) 57.9Gy ± 1.6Gy 0.1cm3 
Optic chiasm (cumulativeEQD2) 53.8Gy ± 1.6Gy 0.1cm3 
  




Figure 3.3.3: Composite of Primary and Secondary Radiation Therapy Treatment Plans for GBM03. 
Patient Journey through Salvage Treatment   
During treatment  
Over the two weeks of treatment the patient’s quality of life and functional scores fluctuated but 
were essentially unchanged on the final day of treatment from baseline.   It is unclear what triggered 
the patient to experience a peak in overall health and quality of life at the middle of her treatment.  
Six weeks post re-irradiation 
The patient remains well and was tolerating Temozolomide chemotherapy well with blood counts 
remaining within normal ranges. She reported an improvement in overall health since finishing 
radiation therapy but a decreased overall quality of life. In the EORTEC BN-20 survey the patient 
reports ‘a little’ difficulty finding the right words. In conversation with the patient during her follow-
up consultation she often apologises for struggling with speech and was quite critical of her ability to 
speak. However, contrary to what the patient thought, the author thought that conversation still 
flows reasonably well and she was able to express herself quite well. She also spoke about her 
former life when she often did presentations in front of large audiences in large lecture halls and 
was proud of her ability to speak well and present well.  
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The patient reported being quite ‘uncertain about the future’, and made several off-hand references 
to her poor prognosis during her follow-up clinic and enquired whether or not hospice involvement 
would be appropriate at this stage. Hospice contact details were provided but the patient was 
reassured that they would not need to be involved at this stage.  
Overall, the patient reported being limited in her hobbies and mentioned that she felt socially 
isolated because she could not play golf anymore. She also talked about her friends struggling to 
interact with her and that they just wanted to talk about her cancer and not about everyday things. 
The radiation oncologist mentioned support groups that are provided by the cancer society as a 
possible place for her to meet like-minded people. The patient was dismissive of this and did not 
want to meet other people with cancer.  
Three months post re-irradiation 
Adjuvant Temozolomide chemotherapy continues to be well tolerated by the patient. She had no 
new deficits and to the observer her speech was stable or improved since her last follow-up 
appointment. She continues to be frustrated by what she considered to be her poor speech and 
memory. A MRI scan was performed and compared to a scan from before salvage radiation. This 
demonstrated stable appearances of the disease and reduced surrounding oedema. 
Four months post re-irradiation 
The patient continued to tolerate TMZ well and has no significant problems. The patient’s self-
reported overall health and quality of life scores improved since last month however many of the 
specific EORTC QLQ-C30 & EROTC-BN20 scores were higher indicating higher levels of symptoms and 
distress. In conversation with the patient her speech and memory seemed largely unchanged over 
the past month. She mentioned that she is feeling a little socially isolated as much of her previous 
social life revolved around golf which she cannot currently play due to lack of coordination.  
Five months post re-irradiation 
Repeat MRI (Figure 3.3.4) showed disease progression over the past two months despite ongoing 
TMZ chemotherapy. The author was unable to attend this follow-up appointment and therefore the 
EORTC questionnaires were not completed. The consultant Radiation Oncologist reported that the 
patient remained well despite radiological progression and was still functioning at a high level with 
some persistent aphasia. Temozolomide chemotherapy was discontinued and the patient was 
referred to Canopy Cancer Care for a medical oncology opinion. The medical oncologist 
recommended changing to Bevacizumab and Irinotecan chemotherapy, starting immediately to 





Figure 3.3.4: Demonstrates progression of patient GBM03’s tumour on MRI.  
Six months post re-irradiation 
MRI showed a response to Bevacizumab and Irinotecan treatment compared with the MRI scan 
taken two months ago in August 2015. Overall, the patient tolerated Bevacizumab and Irinotecan 
well, she reported feeling washed out the day after each cycle (1-cycle per fortnight) and has had 
occasional diarrhoea which was controlled with the antidiarrheal Loperamide.  
 
Quality of Life  
The overall health and quality of life scores and important issues for patient GBM03 are shown in 
Figures 3.3.5, 3.3.6 and 3.3.7. This patient tolerated re-irradiation well; her overall health, quality of 
life scores and severity of symptoms scores remained largely unchanged. The patient experienced 
reasonably mild symptoms of her disease with difficulty in finding the right words and memory being 
the major physical impairments. From a psychosocial perspective her cancer had a far greater impact 
on her. Not working impacted negatively on her self-perception, she also found she was not able to 
play golf anymore which in turn had an impact on her social life. She also found that friends 
struggled to relate to her now that she had a life threatening illness and they expected her to let the 




Figure 3.3.5: Overall Health and Quality of Life scores for patient GBM03. 
 








3.4  Patient GBM04  
Table 3.4.1: Demographic characteristics of patient GBM04. 
Patient Details 
Patient Identifier  GBM04 
Gender and Age M 49yrs 
Karnovski score (at recurrence) 60 
Tumour grade (initial)  WHO Stage 4   MGMT methylated 
Tumour location  Multifocal predominantly right frontal lobe   
Date of initial diagnosis 13/8/2014 
Start of primary treatment 15/9/2014 
Date of recurrence 1/5/2015 
Type of recurrent Clinical progression 
Time to recurrence 9 months  
Start of salvage treatment 11/5/2015 
Survival from salvage treatment 5 months  
Status at Dec 2015 Deceased (5/10/2015) 
 
Patient Characteristics 
The patient was a 49 year old male living in Auckland. He was married and had three children aged 
17, 15 and 13 years old. He managed his own design and print business which kept him very busy. 
He never smoked, had a low alcohol intake, and since his cancer diagnosis had stopped drinking. The 
patient usually ran to keep fit.  
Presentation and Primary treatment 
In August 2014 the patient presented with an approximately one-month history of reduced hearing 
in his left ear. An MRI revealed quite significant intracranial masses with minimal surrounding 
oedema and minimal mass effect. As a 16yr old, the patient (in 1983) was diagnosed with acute 
lymphoblastic leukaemia for which he was treated with cranial irradiation of 24Gy in 16 fractions, 
1.5Gy per fraction, 1 fraction per day, over three and a half weeks. He has remained in remission 
since then. Initial work up was done to confirm if the new masses were a recurrence of 
lymphoblastic leukaemia or a new primary cancer. A burr hole biopsy was performed and confirmed 
the histology of the lesions as GBM (MGMT methylation present).   
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Due to the multifocal nature of the disease the patient received whole brain irradiation of 40Gy in 25 
fractions, 1.6Gy per fraction, 1-fraction per day, 5 fractions per week over 5 weeks. The areas of 
enhancing disease were treated with simultaneous integrated boosts taking the doses in these areas 
to 56.25Gy in 25-fractions (Figure 3.4.1). The treatment was delivered using VMAT. The radiation 
therapy plan took two weeks to create, due to the complexity of the lesions and extent of disease. 
The previous dose to the patient’s brain was not specifically accounted for during radiation therapy 
planning of his primary or salvage treatment for his GBM. He was started on Temozolomide while his 
radiation therapy plan was being created rather than commencing on the first day of treatment as is 
standard practice. Concurrent Temozolomide of 100mg daily was administered over the course of 
radiation treatment. This was followed by adjuvant Temozolomide of 200mg daily for five days per 
month for six months. 
 
Figure 3.4.1: Primary Radiation Therapy Treatment Plan for GBM04. 
Table 3.4.2: Dose to critical structures from primary radiation treatment for GBM04 
Structure  Dose  Volume 
Brain (incl. PTV) 56.25Gy (EDQ2 60Gy) 189cc (12.7%of whole brain volume 
Brainstem 56.4Gy (EQD2 59.3Gy) 0.1cm
3
 






Three months later, the patient had a repeat MRI which showed a partial response to treatment 
(Figure 3.4.2). Overall, the patient tolerated chemotherapy well although he felt too fatigued to run 
which was frustrating for him as it was a way to relax and keep fit.   
 
Figure 3.4.2: Serial MRI Imaging Showing a Partial Response to Primary Treatment of Patient 
GBM04. 
In late December 2014 the patient presented with rapidly progressing weakness in his left leg. An 
MRI of the spine demonstrated abnormalities over 2.5cm at the level of the twelfth thoracic 
vertebrae with mild compression of the spinal cord. This metastasis was treated as a category A 
(treatment to commence within 24hrs) at Auckland City Hospital with the aim of preventing further 
compression of the spinal cord and any further loss of function. Radiation therapy of 20Gy in 5 
fractions, 4Gy per fraction, 1 fraction per day, over one week was delivered. This was a simple plan 
with one direct posterior field in order to start the treatment within 24 hours after confirmation of 
spinal cord compression due to disease. On the evening following the first fraction he was admitted 
with worsening pain and weakness. Subsequent to this the patient developed paraplegia.  
Salvage Treatment  
The MRI in January and March 2015 showed largely stable disease. In May 2015 the patient was 
reviewed complaining of double vision. On examination the patient also presented with partial VI th. 
nerve palsy. Although the patient had multiple areas of enhancement on the scan, it was decided to 
only re-irradiate the areas of the brain responsible for the symptomatic progression of the disease. 
This meant that the high doses of retreated region did not overlap with the area of the brain that 
had previously received simultaneous integrated boost doses. This was done to minimise the acute 
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and late toxicities of the radiation while still achieving the aim of palliating symptoms.  As the patient 
was paraplegic and required daily hoist transfers for treatment, the treatment regime was further 
hypo-fractioned to five fractions rather than the standard ten treatments. A total dose of 20Gy over 
5 fractions, 4Gy per fraction, 1 fraction per day for 5 days over one week was prescribed (Figure 
3.4.3). This provides a lower equivalent dose than 35Gy in 10-fractions however it was necessary in 
order to keep the dose to critical structures within acceptable limits. 
 
Figure 3.4.3: Composite of Primary and Secondary Radiation Therapy Treatment Plans for GBM04 
Table 3.4.3 Composite dose to critical structures from Primary & Secondary Radiation 
therapy for GBM04 
Structure  Dose  Volume 
Brainstem (EQD2)  27.8Gy 0.1cm3 
Optic chiasm (EQD2)  0.3Gy 0.1cm3 
Brain cumulative (non EQD2) 60Gy 45.6cm3 (3.08% of whole brain) 
Brainstem (cumulative EQD2) 87.1Gy ± 2.5Gy 0.1cm3 




Patient Journey through Salvage Treatment   
During treatment  
Over the course of salvage radiation the patient’s overall health and quality of life scores remained 
unchanged. The patient reported needing to rest slightly more at the completion of treatment 
compared to the baseline. This may have been due to the effort of coming in each day for treatment. 
As a paraplegic, multiple hoist transfers were required to help him on and off the treatment couch 
which added to the time that the patient and his wife had to be in the department each day.   
Two weeks post re-irradiation 
In the two weeks post re-irradiation the patient deteriorated symptomatically with a decrease in 
overall health and quality of life. The patient’s deterioration was thought to be partly related to his 
cranial disease and re-irradiation but also due to the presence of spinal metastasis. Therefore, an 
urgent MRI was arranged to assess the extent of disease. Despite his recent deterioration in 
condition the patient, his wife and parents were all keen to continue with active therapy. He was 
prescribed Etoposide chemotherapy of 50mls to be taken daily.  
Six weeks post re-irradiation 
An MRI scan showed a mixed response to therapy with a response to chemotherapy and re-
irradiation in some but not in other areas. In the time since the previous review the patient had 
continued to deteriorate. This was reflected in the QLQ-C30 scores. The patient found it too tiring to 
fill out the entire QLQ-C30 questionnaire and did not complete the BN-20. It may be reasonable to 
assume that the increase in these specific functional scores would have led to a decrease in the 
overall health and quality of life scores. Despite obvious progression and deterioration the patient 
and his family were trying to remain optimistic about the future and were not ready to consider 
stopping active treatment. The patient was referred to a medical oncologist to discuss further 
chemotherapy options. The patient was reviewed by the medical oncologist and offered two 
different treatment options. Lomustine which is on the Pharmac schedule and has a low toxicity 
profile but only a small chance of efficacy was offered. The doublet therapy Bevacizumab and 
Irinotecan was also discussed; the later therapy is not publicly funded and carries a higher toxicity 
profile especially in view of the comorbidities of this patient. The option of no active therapy was 
also discussed given that it was unlikely that active therapy would improve his quality of life.  
The patient and his family opted to try Bevacizumab and Irinotecan. The patient reported lower 
QLQ-C30 scores and a negative impact on family life and financial difficulties. This may be as a result 
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of having to pay for this treatment. The treatment was reasonably well tolerated and the patient 
mentioned that he had managed to get out of the house to watch a football game at the local park.  
Three months post re-irradiation 
The patient was reviewed by hospice because he was experiencing unmanageable back and lower 
limb pain. Three weeks ago the patient had discontinued pain relief due to concerns about being 
excessively sedated and constipated however it was decided to restart pain medication. The patient, 
his wife and children were also meeting with the hospice family support counsellor.  
Four months post re-irradiation 
The patient continued to show clinical decline and it was decided to discontinue active therapy. He 
passed away in early October five months after re-irradiation. 
Quality of Life 
The overall health and quality of life scores and important issues for this patient are shown in Figures 
3.4.4, 3.4.5 and 3.4.6. Patient GBM04 tolerated re-irradiation reasonably well; his overall health, 
quality of life and severity of symptoms scores remained largely unchanged over the course of 
salvage radiation. This patient had wide spread disease both in the brain and spinal column. 
Although a partial response to treatment was seen in the area that was re-irradiated, there was a 
rapid deterioration in his condition and disease progression elsewhere. A majority of this decline is 
not captured by the EORTC scores as the patient was too unwell to complete the questionnaires. The 
patient and his family were keen to pursue active therapy despite its limited efficacy; this may have 





Figure 3.4.4: Overall Health and Quality Life Scores for Patient GBM04. 
 
 









3.5 Patient GBM05  
Table 3.5.1: Demographic characteristics of patient GBM05 
Patient Identifier  GBM05 
Gender and Age M 69yrs  
Karnovski score (at recurrence) 100 
Tumour grade (initial)  WHO Grade IV      MGMT unmethylated  
Tumour location  Right parietal tumour  
Date of initial diagnosis 3/10/2014 
Start of primary treatment 6/11/2014 
Time to salvage treatment 7 months  
Type of recurrence  Radiological 
Start of salvage treatment 8/06/2015 
Survival from salvage treatment 6 months  
Status at 12/2015 Alive 
 
Patient Characteristics 
This patient is a 69 year old male; he and his wife of almost 50 years live in Auckland. They have two 
adult children and three grandchildren. At the time of commencing salvage treatment the patient 
was still working full time selling advertising for a newspaper. He enjoys spending time with his 
grandchildren and watching football.   
Presentation and Primary treatment 
In October 2014 the patient presented with vertigo and bilateral lower limb weakness. An MRI 
showed three enhancing masses in the right parietal region. The patient proceeded to debulking 
surgery and the histology was confirmed as GBM with normal MGMT activity. An MRI showed some 
enhancement, which was thought to be post-surgical change rather than residual tumour. Following 
surgery, radiation therapy of 60Gy in 30 fractions, 2Gy per fraction, 1 fraction per day, 5 fractions 
per week over 6 weeks was prescribed. This was delivered using VMAT (Figure 3.5.1). Concurrent 
Temozolomide was prescribed, followed by adjuvant Temozolomide for 5 days of every month for 6 




Figure 3.5.1: Primary Radiation Therapy Treatment Plan for GBM05.  
Table 3.5.2: Dose to critical structures from primary radiation treatment for GBM05 
Structure  Dose  Volume 
Brain (incl. PTV) 60Gy 166 cm
3
 (10% of whole brain volume) 
Brainstem 52.4Gy  0.1cm
3
 
Optic chiasm 21.2Gy  0.1cm
3
 
PTV (Maroon) 57Gy 57Gy 99% 
CTV (red) 59.4Gy 59.4Gy 98.69% 
Following radiation treatment the patient recovered very well and was able to enjoy summer. He 
had no seizures or headaches. He returned to fulltime work which he was enjoying and coping well 
with.  
Three months following primary radiation therapy, an MRI showed a reduction in size of one 
enhancing region compared with the post-surgery MRI. The other enhancing lesions were larger, 
indicating a partial response to therapy and early follow-up was recommended. Monthly 
Temozolomide was continued and a follow-up MRI scheduled for one month’s time. In March 2015 
the patient had a follow-up MRI which showed stable disease. In April 2015 a FET-PET scan was 
performed to distinguish between pseudo-progression and residual disease. The enhancing mass 
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was confirmed as residual active tumour. At the neuro-oncology multidisciplinary meeting it was 
decided to surgically excise the residual disease followed by salvage radiation.  
Salvage Treatment  
In May 2015 the patient’s residual tumour was resected and the histology was confirmed as GBM. 
Post-operative imaging showed that the bulk of the tumour was removed with some residual 
enhancement around the medial and deep aspect of the tumour bed. Two weeks after surgery the 
patient had a CT scan to plan his radiation therapy treatment. Four weeks post-surgery the patient 
commenced salvage radiation therapy. 35Gy in 10 fractions, 3.5Gy per fraction, 1 fraction per day, 5 
fractions per week, over two weeks was prescribed (Figure 3.5.2). After 6 fractions (21Gy) the 
patient had a grand mal seizure. He was hospitalised for three days after this episode and made a 
very good recovery; he was communicative and showed no sign of cognitive impairment. After the 
seizure he was started on anticonvulsants and did not experience any further seizures. An urgent 
MRI was organised to determine the cause of the seizure. This MRI showed disease progression from 
the previous scan preformed one month ago, immediately after surgery. The patient had a one week 
break in treatment to allow time for his treatment plan to be modified to encompass the new area 
and for him to recover from his seizure. The new area was treated to 20Gy in 5 fractions.  
 




Table 3.5.3: Composite dose to critical structures from Primary & Secondary Radiation therapy 
for GBM05 
Structure  Dose  Volume 
Brainstem 1.0Gy  0.1cm3 
Optic chiasm 0.9Gy  0.1cm3 
Brain cumulative (not EQD2) 60Gy 284.6 cm3 (17.4%) 
Brainstem (cumulative EQD2) 54.6Gy ± 0.6Gy 0.1cm3 
Optic chiasm (cumulativeEQD2) 15.3Gy ± 1.0Gy 0.1cm3 
Patient Journey through Salvage Treatment   
During treatment 
Prior to commencing salvage treatment the patient was very well and he was working full time. The 
recommendation to have salvage treatment was based on radiological disease rather than clinical 
symptoms with the aim to delay any clinical deterioration. As discussed above, mid-way through the 
treatment the patient experienced a grand mal seizure due to disease progression. As expected, this 
correlated with decreased quality of life and health scores and with deterioration in his condition as 
this was his first seizure. The patient reported pain but the site of this pain was unclear and the 
patient had not reported headaches previously. Therefore, this pain may have been unrelated to the 
brain tumour or any treatments. His need for rest increased sharply mid-way through his treatment 
(after his seizure) but reduced towards the end of treatment.  
At the end of treatment follow-up the patient seemed to have largely recovered from his seizure and 
showed no signs of cognitive impairment. He was somewhat apprehensive as to what the future 
may hold. He has a son who lives in Brisbane whom he was keen to visit and had a holiday in Fiji 
planned with his wife. He was advised that it was safe to go on these holidays but seek medical 
assistance promptly if he noticed any ill health and to continue with his anti-seizure medication. The 
patient had a great time on both of these trips and experienced no seizures.     
Two months post re-irradiation 
The patient had a follow-up MRI two months after finishing radiation therapy. This MRI showed that 
the disease was essentially stable with slightly decreased enhancement. The radiation oncologist 
referred the patient to a medical oncologist for chemotherapy. The patient has attended no further 




Six months post re-irradiation 
From the patients notes it is unclear if he ever received chemotherapy. A follow-up MRI requested 
by the medical oncologist demonstrated stable disease. Perfusion MRI demonstrates decreased 
blood flow in the irradiated area indicating a necrotic tissue at the centre of the tumour.  
 
 
Figure 3.5.3 MRI imaging of patient GBM05 6-months post re-irradiation. A) Demonstrates stable 
disease visualised on MRI. B) Demonstrates decreased blood flow in the tumour visualised using 
perfusion MRI.  
 
Quality of Life 
The overall health and quality of life scores and important issues for this patient are shown in Figures 
3.5.4 and 3.5.5. Patient GBM05 reported a significant change in his overall health, quality of life and 
severity of symptoms scores during salvage re-irradiation. This change was attributed to disease 
progression and the resultant grand mal seizure he experienced rather than as a result of the 
radiation therapy. As well as the physical impact of this decline it impacted on him psychologically as 
well. At the beginning of his salvage therapy he was asymptomatic of his tumour however by the 
end of the salvage radiation he felt he had a significant setback in his condition as a result of the 




Figure 3.5.4: Overall Health and Quality of Life Scores for Patient GBM05 
 
 





3.6 Patient GBM06  
Table 3.6.1: Demographic characteristics of patient GBM06 
Patient Identifier  GBM06 
Gender and Age Female 26yrs old 
Karnovski score (at recurrence) 100 
Tumour grade (initial)  Anaplastic astrocytoma WHO grade III 
Tumour location  Left Frontal Temporal Lobe 
Date of initial diagnosis Feb 2011 
Start of primary treatment April 2011 
Date of recurrence May 2015 
Time to recurrence 4 years 3 months 
Type of recurrence  Radiological progression 
Start of salvage treatment June 2015 
Survival from salvage treatment  6 months  
Status at 12/2015 Alive 
Patient Characteristics 
The patient is a 26 year old female; she lives with her ten year old daughter in Auckland. She has a 
partner with whom she had planned to have more children. She works as a duty manager of a retail 
outlet. She continued to work throughout her treatment as much as her health would allow.  
Presentation and Primary treatment 
The patient presented with visual field abnormalities, she had an MRI scan which confirmed a mass 
in her left frontal temporal lobe. She went through debulking surgery, followed by concurrent 
radiation and Temozolomide chemotherapy. The radiation dose prescribed was 60Gy in 30-fractions, 
2Gy per fraction, 1 fraction per day, 5 fractions per week over 6 weeks (Figure 3.6.1). This was 
delivered at Auckland City Hospital Radiation Therapy clinic. Radiation was delivered using a four 
field 3D conformal treatment delivery technique. This was followed by 6 cycles of adjuvant 





Figure 3.6.1: Primary Radiation Therapy Treatment Plan for Patient GBM06 
Table 3.6.2: Dose to critical structures from primary radiation treatment for GBM06 
Structure  Dose  Volume 
Brain (incl. PTV) 60Gy 62.5cm
3
 (4.3% of whole brain volume) 
Brainstem 24.2Gy  0.1cm
3
 
Optic chiasm 38.1Gy  0.1cm
3
 
Between 2011 and 2015 the patient had six monthly MRIs to monitor any signs of recurrence. The 
April 2015 MRI showed some abnormality. In order to distinguish between surgical and treatment-
related atrophy, and disease progression a FET-PET CT scan was performed. This PET showed 
metabolic activity consistent with recurrent tumour rather than brain atrophy. This scan was 
correlated with the MRI and confirmed recurrent disease. In May 2015 the patient’s scans were 
reviewed at a neuro oncology multidisciplinary meeting and salvage therapy was recommended.   
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Salvage Treatment  
The patient was reviewed by a surgeon to consider surgical resection of the recurrence. It was felt 
that the tumour was too close to Broca’s area of the brain and would likely result in speech deficits. 
Therefore, the patient was prescribed 365Gy in 10-fractions, 3.5Gy per fraction, 1 fraction per day, 5 
fractions per week, over two weeks (Figure 3.6.2). This was to be followed by six months of adjuvant 
Temozolomide 300mgs daily for five days a month.    
 
Figure 3.6.3: Composite of Primary and Secondary Radiation Therapy Treatment Plans for GBM06.  
Table 3.6.3 Composite dose to critical structures from Primary & Secondary Radiation therapy 
for GBM02 
Structure  Dose  Volume 
Brainstem 5.16Gy  0.1cm3 
Optic chiasm 1.59Gy  0.1cm3 
Brain cumulative (not EQD2) 60Gy 13.55% 
Brainstem (cumulative EQD2) 43.5Gy ± 4.6Gy 0.1cm3 




Patient Journey through Salvage Treatment   
During treatment  
Over the course of her treatment the patient reported decreased overall health and quality of life 
scores. Many of the elements that she reported as being quite distressing were psychosocial in 
nature rather than physical impairments of the disease or treatment. Midway through the patient’s 
treatment she was told that as she was at risk of having a seizure she should not be driving. This had 
a large impact on her as she was very independent, driving herself to work and picking her daughter 
up from school. The patient’s headaches were thought to be due to treatment-related swelling and 
she was prescribed Dexamethasone to decrease the swelling. The patient reported that she found 
the Dexamethasone affected her ability to sleep and increased her appetite. She was quite worried 
and uncertain about her future. Even though she was on antidepressants throughout treatment she 
was still prone to anxiety. 
Two weeks post re-irradiation 
The patient attended the emergency department with a headache, difficulty with speech, a right 
sided facial droop, limb weakness and tingling. She was meant to take a low dose of Dexamethasone 
after she had completed radiation therapy however she was only intermittently compliant with 
taking Dexamethasone. A CT scan showed significant oedema and a resultant mass effect. The 
Dexamethasone prescription was increased to reduce the acute swelling and the patient reported 
feeling much more normal again the following day.  
Six weeks post re-irradiation 
The patient’s headaches from treatment-related swelling had reduced six weeks after treatment. 
She was still not allowed to drive and this continued to disrupt her family life. Prior to starting 
Temozolomide chemotherapy the patient wanted to look into fertility preservation. As she already 
had a child she was not eligible for publicly funded fertility preservation, therefore she did not 
explore this option any further. The patient continued to worry and be uncertain about the future. 
Her radiation oncologist referred her for a psychiatric consultation as she was having significant 
anxiety attacks.  
Two months post re-irradiation 
The patient had a follow-up MRI scan which showed areas of enhancement around the margins of a 
central mass of tumour necrosis. A FET-PET scan was done to distinguish between active tumour and 
radiation-induced changes. The PET scan revealed that the tumour area which had had been re-
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irradiated had largely resolved. However, a new enhancing lesion inferior to the area previously 
treated was diagnosed. Therefore, the patient was started on adjuvant Temozolomide of 300mg 
daily for five days of each month for six months.   
Three months post re-irradiation 
The patient experienced nausea on Temozolomide, this was managed with the antiemetics Zofran 
and Maxolon as well as a laxative because these antiemetics can cause constipation. 
Four months post re-irradiation 
The patient continued on Temozolomide and a low dose (2mg) of Dexamethasone. For a few days 
she skipped her Dexamethasone and experienced acute affects that resulted in admission to the 
emergency department again. She presented with aphasia, right sided facial droop, limb weakness 
and tingling. At the onset of these symptoms prior to going to the hospital she took 2mg of 
Dexamethasone. While at the hospital she showed an improvement. An MRI scan was performed 
and showed minimal progression of disease.   
Five months post re-irradiation 
A repeat MRI demonstrated stable disease.  
 
Quality of Life 
The overall health and quality of life scores and important issues for this patient are shown in Figures 
3.6.3 and 3.6.4. Overall patient GBM06 reported a drop in overall health and quality of life scores 
and an increase in severity of symptoms scores in some domains. From a physical perspective the 
patient tolerated salvage re-irradiation well, even though the number and severity of headaches 
increased towards the end of treatment. She became more concerned about disruption to family 
life, possibly as she lost her independence by not being able to drive part way through her radiation 
therapy. She found out that she was not eligible for publicly funded fertility preservation, this 
impacted on her and her partner’s previous plans to have more children. This young patient 
experienced high levels of uncertainty about the future and worried a lot. She was particularly 
worried about her ability to look after her daughter in the future and what would happen when she 




Figure 3.6.3: Overall Health and Quality of Life Scores for Patient GBM06  
 
 





3.7 Patient GBM07  
Table 3.7.1: Demographic characteristics of patient GBM07. 
Patient Identifier  GBM07 
Gender and Age F 85yrs  
Karnovski score (at recurrence) 100 
Tumour grade (initial)  Glioblastoma multiforme MGMT unmethylated  
Tumour location  Left frontal lobe 
Date of initial diagnosis November 2014 
Start of primary treatment January 2015 
Time to salvage therapy 6 months  
Start of salvage treatment June 2015 
Type of recurrence  Radiological 
Survival from salvage treatment  6 months  
Status at 12/2015 Alive 
Patient Characteristics 
The patient is an 85 year old lady; she lives in Auckland with her husband. Prior to this diagnosis the 
patient was in good health and a keen gardener. She has adult children who are a great support to 
her.  
Presentation and Primary treatment 
The patient presented with progressive right arm and leg weakness over the past month. A CT scan 
demonstrated a left frontal mass. Debulking surgery was performed and the post-operative image 
showed that the tumour had been completely excised. Due to the patient’s age a hypo-fractioned 
course of radiation (40Gy in 15-fractions) was considered. However, due to her good performance 
status and complete resection she was prescribed 60Gy in 30 fractions, 2Gy per fraction, 1 fraction 
per day, 5 fractions per week over 6 weeks (Figure 3.7.1). Treatment was delivered using VMAT. 
Temozolomide at 100mg daily was prescribed concurrently with the radiation, followed by adjuvant 
Temozolomide of 300mg daily for five days each month.  
The patient tolerated radiation treatment well, temporary alopecia and fatigue being the major side 
effects. The patient also tolerated her first cycle of adjuvant Temozolomide well. She was prescribed 
Zofran as antiemetic cover. The patient’s platelets dropped significantly therefore the dose of 




Figure 3.7.1: Primary Radiation Therapy Plan for GBM07. 
Table 3.7.2: Dose to critical structures from primary radiation treatment for GBM07.  
Structure  Dose  Volume 
Brain (incl. PTV) 60Gy 22.05cc  
Brainstem 17.2Gy  0.1cm
3
 
Optic chiasm 12.0Gy  0.1cm
3
 
Salvage Treatment  
In June 2015 the patient remained well clinically, however, a follow-up MRI showed some residual 
disease. Overall, there was much less oedema surrounding the tumour and a smaller mass effect. 
Due to the location of this tumour abutting the left lateral ventricle there was a risk of 
leptomeningeal disease dissemination. Therefore, re-irradiation to this site was recommended. 





Figure 3.7.3: Composite of Primary and Secondary Radiation Therapy Treatment Plans for GBM07. 
Table 3.7.3: Composite dose to critical structures from Primary & Secondary Radiation therapy 
for GBM07.  
Structure  Dose  Volume 
Brainstem 2.6Gy  0.1cm3 
Optic chiasm 2.6Gy  0.1cm3 
Brain cumulative  60Gy 18.7% 
Brainstem (cumulative EQD2) 34.9Gy ± 1.2Gy 0.1cm3 
Optic chiasm (cumulativeEQD2) 30.7Gy ± 136Gy 0.1cm3 
 
Patient Journey through Salvage Treatment   
During treatment 
The patient’s overall health and quality of life scores remained relatively stable throughout the re-
irradiation treatment and the two weeks following. Fatigue and feeling unsteady on her feet were 
major problems for this patient and possibly impacted on the other areas that she struggled with 
such as doing gardening and taking walks. During treatment she felt that her condition was causing 
disruption to family life. This may in part have been due to needing someone to bring her in for her 
daily treatments. The patient’s skin became itchier over the course of treatment which was likely 
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due to radiation induced dermatitis. The patient was given hydrocortisone cream part way through 
treatment, which likely reduced the itch and reduced symptom scoring towards the end of 
treatment.  
Two weeks post re-irradiation 
The patient remained well and showed no signs of progression, however, the oncologist prescribed 
her Lomustine 40mg daily for three days per month in order to delay progression. 
Six weeks post re-irradiation 
The patient had a recent MRI which shows essentially stable disease. She is to continue on 
Lomustine chemotherapy as she is tolerating this well with tiredness being the major concern.  
Four months post re-irradiation 
The patients overall health and quality of life scores remain stable; this can be correlated with stable 
disease on MRI. Lomustine chemotherapy of 40mgs daily for three days of the month is to be 
continued as the patient is not experiencing hematologic toxicity from this. At the follow-up 
consultation the patient reported feeling very tired and this was impacting on her ability to i.e. go 
grocery shopping. This is reflected in higher levels of severity of symptoms scores. 
Quality of Life 
The overall health and quality of life scores and important issues for this patient are shown in Figures 
3.7.3, 3.7.4 and 3.7.5. Patient GBM07 reported reasonably stable overall health and quality of life 
scores during treatment and in the months following. Her scores for overall health and quality of life 
were not high and she reported high levels of severity of symptoms scores, particularly in physical 
domains such as taking a long walk and was limited in her daily activities and hobbies. She struggled 
‘quite a bit’ to ‘very much’ carrying out strenuous activities, which is to be expected for someone in 





Figure 3.7.3. Overall Health and QOL scores of patient GBM07. 
 









3.8 Summary of Results  
The journey through salvage re-irradiation and during follow-up is unique for each patient. 
Differences in presentation location, size and primary treatment of the primary lesions as well as 
salvage treatment varies between patients as can be seen in Tables 3.8 and 3.9. 
Table 3.8: Summary of presentation and primary treatment of GBM patients in the 
study. 
ID Age Disease grade Primary RT Px Primary Chemo 
Overall 
Survival 
GBM01 50yrs IV 
59.4Gy 33#s 
3D-CRT 
Con TMZ 100mg  





III – IV 
MGMT 
unmethylated 
60Gy 30#s VMAT 
Con TMZ 80mg 
Adj 200mg 5d/m 
6months 
1yr 3 months  
GBM03 69yrs IV 60Gy 3#s VMAT 
Con TMZ 100mg 
Adj 320mg 5d/m 
6m 





Whole brain 40Gy 25#s 
SIB 56.25Gy in 25#s 
VMAT 
Neo Adj & conc 
TMZ100mg/d 
Adj TMZ 200mg 
5d/m  





60Gy 30#s VMAT 
Adj & con TMZ px 
dose not available  
1yr 1 month* 
GBM06 26yrs III 60Gy 30#s 3DCRT 
Adj & con TMZ px 
dose not available 
4yrs 6 moths* 
GBM07 85yrs IV 60Gy 30#s VMAT 
Con TMZ 100mg 
Adj TMZ 300mg 
5d/m, reduced 
due to toxicity 
250mg   
1 year* 
* = patient alive at 1
st
 December 2015.  Con = Concurrent ,  Adj = adjuvant, TMZ = Temozolomide, M = 
month, D = day. 
A total of seven patients took part in this study, two were male and five were female; with ages 
varying from 26 years to 85 years. 
Six of the seven patients in the study were diagnosed with GBM at the time of their initial diagnosis. 
One patient (GBM06) was diagnosed with Anaplastic Astrocytoma. Methylation status of the MGMT 
was determined for three of the patients; in two of these patients, MGMT was normal 
(unmethylated) and would have been capable of repairing Temozolomide induced DNA damage. 
Only one patient (GBM04) had methylated MGMT, incapable of repairing Temozolomide-induced 
78 
 
DNA damage. He was given Temozolomide as part of his primary treatment, however, he 
experienced disease progression during the adjuvant phase of Temozolomide chemotherapy. 
With respect to primary surgery, five patients had debulking surgery, patient GBM04 had a biopsy 
only and patient GBM02 had no surgery at all due to her age and general condition. Consistent with 
the current gold standard, five patients received 60Gy in 30 fractions. The dose regime differed 
slightly for two patients (GBM01 and GBM04) however they received biologically equivalent doses to 
the standard of care. Concurrent and adjuvant Temozolomide was administered, dose schedule 
varied between patients due to clinical factors. Dose schedules were not available for two of the 
patients. Two of the patients (GBM01 and GBM06) were treated using 3D-confromal radiation 
therapy delivery; all others were treated using VMAT. This is reflective of the technological advances 
that occurred between when GBM01 and GBM06 were treated four years ago and more recently 
when all other patients were treated.  





















Adj TMZ 100mg 
Con TMZ 300mg 
5d/m 4-cycles 
10 cycles Bev & 
Irri 
5-cycles Avastin 
1cycle each f/n 
15 months* 




50mg 14d/m  
 7 months 
GBM03 10 months Radiological 
35Gy 10#s 
 
Con TMZ 300mg 
5d/m 2-cycles 
Bev & Irri 7-
cycles Avastin 1-
cyle every f/n 
10 months* 
GBM04 9 months Clinical 
20Gy 5#s  
 
Con Bev & Irri 1-
cycle 
 5 months 




20Gy 5#s  
  6 months* 
GBM06 
4 years 3 
months 
Radiological 35Gy 10#s  
Adj TMZ 300mg 
5d/m 6m 
 6 months*  
GBM07 6 months  Radiological 35Gy 10#s  
Adj CCNU 40mg 
3d/m  
 6 months*  
Con = Concurrent ,  Adj. = adjuvant, TMZ = Temozolomide, Bev = Bevacizumab, Irri = irinotecan M = 
month, D = day * = alive at 1st December 2015 #=fraction 
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Time to progression varied between patients from four years three months to 10 months. Disease 
progression was mainly picked up radiologically (5 patients), rather than through presentation of 
clinical symptoms (2 patients). Only patient GBM05 had residual tumour resected after disease 
progression.  
Salvage radiation was delivered using VMAT with a dose of 35Gy in 10 fractions for 5 patients. One 
patient (GBM04) received 20Gy in 5 fractions, 5 fractions were deemed more appropriate in light of 
his paraplegia and a lower equivalent dose due to the extensive nature of his primary radiation 
treatment. Patient GBM05 also received a non-standard treatment fractionation due to progression 
part way through his salvage re-irradiation. Some areas received 41Gy in 11 fractions to ensure that 
the new areas of enhancement received 20Gy in 5 fractions. An increase in the dose per day was 
seen as beneficial as it limited the total treatment time in view of the few days break he had while a 
new radiation plan was developed and he was hospitalised as a result of his seizure.  
Each patient responded differently, both physically and psychosocially, to having a recurrent brain 
tumour and its treatments. Figure 3.8 shows the averaged overall health and quality of life scores at 
time points since re-irradiation of all seven patients. During treatment, five of the seven patients 
reported a decrease in overall health and quality of life. This decrease may be attributed to 
symptoms of the radiation treatment, the disease or a combination of both. For instance, patient 
GBM06 experienced an increase in headaches over the course of treatment that was likely a result of 
radiation induced swelling of the brain, impacting on her overall health and quality of life scores. 
GBM05’s decrease in overall health and quality of life scores is likely explained by disease 
progression during treatment.  
The direct physical symptoms of treatment varied between patients but were reasonably minor for 
all patients. One patient experienced itchy skin as a result of radiation induced dermatitis, most 
patients experienced an exacerbation of baseline symptoms as a result of brain swelling such as 
patient GBM06’s headaches. Many questions in the ERORTC questionnaires capture fatigue 
responses such as ‘did you need to rest’ and ‘were you tired’. All seven patients reported an increase 
in one or more fatigue type domain of the questionnaire. Fatigue occurs as physical response to 
radiation therapy but these effects can be exacerbated by the logistical issues of coming in for 
treatment each day and the stress associated with treatment delivery.  
Radiation treatment also directly affects patients on a psychosocial level. Due to their brain tumours 
none of the patients in this study were allowed to drive. Therefore, they relied on others to bring 
them into treatment. Two patients also had to travel to Auckland from out of town for treatment. 
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These factors correlate to almost all patients reporting levels of ‘disruption to family life’, and their 
‘physical condition or medical treatment impacting on family or social activities.’ 
Almost all patients in this trial experienced psychological distress, all patients except GBM07 
reported at least ‘a little’ worry or depression on their EORTC questionnaires. All patients except 
GBM04 felt at least ‘a little’ uncertain about the future.   
The tumour responses to salvage radiation and chemotherapy were varied.  No complete responses 
were achieved. Four patients achieved a partial response and three patients’ disease remained 
stable following salvage radiation therapy. Due to residual disease salvage chemotherapy using a 
variety of regimes was recommended. A total of six patients had salvage chemotherapy, three 
patients were prescribed Temozolomide, one patient received Etoposide, one patient received 
Avastin plus Irinotecan and one patient was prescribed Lomustine. Two patients received secondary 
salvage chemotherapy (Bevacizumab and Irinotecan) upon further progression. Bevacizumab and 
Irinotecan were recommended for another patient, however, it is unclear if chemotherapy was 
received due to funding problems.  
 






Chapter 4   Discussion 
As high grade gliomas are incurable and patients relapse eventually, salvage treatments such as 
hypo-fractionated radiation therapy are offered not only to extend life but also to improve patients’ 
overall QOL and HRQOL. The results chapter describes the journey of seven high grade glioma 
patients through their salvage radiation treatment and the period immediately after completion of 
treatment. The impact of salvage radiation was assessed in several ways. The author attended 
consultations with the Radiation Oncologist to note any information regarding side effects of 
treatments, disease symptoms and how they were coping on a day-to-day basis. Treatment and 
health-related information was obtained from patient notes. The patients themselves filled in the 
validated EORTC QLQ-C30 and BN-20 at the start, during and following salvage radiation. 
This chapter discusses some of the issues surrounding these cancer journeys, the limitations of the 
study and suggests some avenues for future research. 
4.1  Heterogeneity of the patient journeys 
The most noticeable aspect of this research has been the heterogeneity of this small patient cohort. 
Although each cancer patient’s journey is unique, it seemed that the journeys of this small cohort of 
patients with recurrent high grade glioma were extremely varied. As expected, the range of active 
and supportive treatments patients received depended on location of the tumour, previous 
treatments, time between primary treatment and recurrence as well as age and patient preference. 
The patients themselves had very different expectations of their health and possible side effects 
associated with their tumour and treatments. They also varied a lot in their level of acceptance of 
those side effects and their prognosis. The level of acceptance of the disease and diagnosis of family 
and friends also affected patient’s level of acceptance. For instance when GBM04 appeared to want 
to continue with active treatment it was in fact his family who were not willing to give up yet. 
Expectations of Health and Health Related Quality of Life 
Although there were only seven patients in this study, the age range was wide, from 26 to 85 years 
old. Through life people’s attitudes towards health and their expectations of their health change. 
People often use their peer group as a point of reference for what is ‘normal’. For example patient 
GMB06 was a 26 year old woman who was married, had a ten year old child and had a reasonably 
long time between primary treatment and progression (four years). She had high expectations of her 
health and quality of life as could be expected of someone this young. It was very important to her 
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that she kept working throughout treatment; this was as much for mental health and keeping her 
routines as it was for financial reasons. Interestingly, she was the only patient who did not always 
take her Dexamethasone. She did not like the side effects of weight gain and would stop taking it 
from time to time; this usually resulted in a significant worsening of her condition and an admission 
to hospital. Perhaps she could not accept that she needed the Dexamethasone to remain well and 
therefore did not see compliance as paramount. Depression can be a risk factor for noncompliance 
with medical treatments, research has shown that patients with depression are three times more 
likely to be non-compliant with medical treatments [92]. At the time that consent was obtained for 
patient GBM06 expressed that she did not feel that she would add any insight in this observational 
study as she did not have any of the problems mentioned in the HRQOL questionnaires. Compared 
to other patients she had reasonably mild physical symptoms with mild headaches being her main 
persistent symptom of disease. Psychosocial issues were the major area of concern for this patient; 
she consistently scored very high levels of distress with uncertainty about the future. Carlson and 
colleagues [41] assessed the levels of untreated distress in 3,095 cancer patients using The Brief 
Symptom Inventory checklist over a period of four weeks. The authors found higher levels of distress 
in women, younger people, and people with lower socioeconomic status; practical, family, emotional 
and physical problems and patients with a worse prognosis. Distress was defined according to the 
National Comprehensive Cancer Network definition (2002) [93]. 
Two patients in the middle age range, GBM01 and GBM04 (50yrs and 49yrs old respectively), both 
had high expectations for their health but seemed more accepting of the physical implications of 
their disease and adapted their lifestyle to accommodate their limitations. Both were also in very 
supportive relationships with partners very willing to help physically and open to adapt their lifestyle 
to fit their reduced capabilities.  
Patient GBM05 was a 69 year old man whose expectation of his health altered significantly over the 
course of his salvage treatment. When he commenced treatment he did not have symptomatic 
progression but had only had a partial response to primary treatment. He was well and working full 
time, and had an active life looking after his grandchildren. However, part way through his salvage 
radiation therapy he experienced a grand mal seizure, this had a profound impact on his self-
assessment of his health as it was the first major symptom that he had had of having a brain tumour. 
He had planned to go on holiday (to Fiji) after finishing his salvage treatment however he and his 
family were concerned about him having another ‘turn for the worse’ while away from good medical 
facilities. He was reassured by his Radiation Oncologist that it was safe for him to go as he was now 
on antiepileptic medications. The patient’s expectations of his health had been severely diminished 
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by his seizure and needed to be restored by his doctor so that he could continue to live a full life 
albeit with an awareness of what to do should challenges arise. It also perhaps made the patient 
face the realities of what the future may hold when disease progression does occur. Zabora and 
colleges [94] determined the prevalence of physiological distress among 4,496 cancer patients. 
Patients at their centre had previously completed a Brief Symptom Inventory to detect physiological 
distress. The patients (median age 57, range 17-95 years) ranged in their type of cancer and 
prognosis. The authors reported that over 50% of patients with a brain tumour diagnosis suffered 
from depression and anxiety. In this thesis six of seven patients reported at least ‘a little’ anxiety and 
depression at some point in their salvage treatment journey.  
The two patients in their 80’s (GBM02 and GBM07) had reasonably low expectations of their health 
compared with patients GBM05 and GBM06 and seemed to take set-backs in their conditions in 
their stride and easily adjusted their lives to accommodate their ‘new normal.’ GBM02 struggled 
somewhat with her memory, however she joked that she and her husband were both in their 80s 
and that he struggled with his memory too. GBM07 found that going shopping was a bit too tiring 
for her now; she would go for the outing but when she became tired she would make her way back 
to the car and wait for her husband to return. Both of them also joked about their brain tumours 
being a good excuse to be able to finally put their feet up and relax after leading busy lives.    
Acceptance of disease and prognosis 
Survival statistics and prognostic indicators are not helpful to the individual patient. Some patients 
seem to “beat the odds” such as patient GBM01, a 50 year old woman who was diagnosed with a 
brain tumour after suffering a series of seizures. At the time of her initial diagnosis the patient 
stopped working and she and her husband moved to Taupo for a change in pace, even though there 
was a period of almost five years between her primary treatment and symptomatic recurrence of 
her brain tumour. At the time of her initial diagnosis she would have been told that she had an 
incurable brain tumour and in very general terms the likely prognosis would have been discussed. 
This played an important role in the couple’s decision to completely change their lifestyle. At the 
time of recurrence she and her husband seemed very well informed and realistic about what the 
future might hold. She was keen to pursue all avenues of active treatment however they did remain 
realistic that the treatment was aiming to prevent symptomatic progression and that the prognosis 
from this point on was limited. Discussions around prognosis when they came up in her routine 
follow-up appointments were generally quite light hearted and discussed with relative ease. Perhaps 
living long term with an incurable illness builds up resilience to such conversations, at least in some 
patients.   
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HRQOL was a secondary endpoint, of the Stupp trial [2] that established the current gold standard of 
primary treatment for GBM. This RCT followed 573 patients with newly diagnosed GBM during 
treatment and for four months following treatment. Taphoorn and colleagues [88] described that 
‘future uncertainty’ decreased over time. The authors proposed that this may be because as patients 
with cancer adapt to the situation they become more accepting and able to face their mortality.  
Insider vulnerability  
In her formative years patient GBM03 was a theatre nurse. When discussions came up around her 
prognosis she had a very no nonsense attitude and did not shy away from discussions about her 
mortality. Research conducted by DeMarco and colleagues [95] found that nurses diagnosed with 
cancer are at risk of additional distress due to their knowledge of the healthcare process and 
content; and also with their knowledge of what is still to come. This additional distress that nurses 
experience at cancer diagnosis has been termed ‘insider vulnerability.’ In contrast to these findings, 
patient GBM03’s experiences with cancer patients in her role as a theatre nurse may have made her 
very aware of the morbidity and mortality associated with cancer and wanted her oncologist to be 
open and frank with her about her prognosis.  
Previous Cancer Diagnosis 
Having had a previous cancer diagnosis may have affected accepting a brain tumour diagnosis and its 
impact on daily life for patient GBM04, a 49 year old man married with three teenage children. 
Three months after completing his primary treatment patient GBM04 developed a spinal cord 
metastasis that resulted in paraplegia due to damage to the spinal cord. This patient and his wife 
adapted very well to his paraplegia. Perhaps experiences of his childhood treatments made him 
more able to adapt to the patient role. He retained some autonomy over his healthcare and day-to-
day decisions such as staying to have a coffee with the radiation therapists after his final treatment. 
His wife advocated well for his independence however assisted willingly with care that he required 
help with such as bathing and maintaining his catheter. Although patient GBM04 seemed very 
accepting of the morbidity of his condition, he and his family (parents, wife and children) were less 
accepting of the overall prognosis and were very reluctant to cease active treatment despite limited 
efficacy. There are many factors that may have played a role in this. GBM04 had had lymphoblastic 
leukaemia as a teenager, during treatment of this life threatening illness his parents no doubt fought 
for their son to survive. As he had been cured of his leukaemia this perhaps gave him and his family a 
greater belief that he would be cured of his GBM also.  
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This patient also had teenage children; he may have felt that he needed to actively fight this cancer 
in order to stay in their lives as long as possible. The time between initial diagnosis in September 
2014 and his death 13 months later in October 2015 would have given him and his family a limited 
time to come to terms with his diagnosis and a particularly short time before his disease gave him 
significant morbidity and ultimately claimed his life.  
Research has demonstrated that a previous cancer diagnosis in childhood impacts on future health 
decisions and self-ratings of health. Patients with a previous cancer diagnosis were either more likely 
to underreport symptoms or to be hyper vigilant about their health [96]. Patient GBM04 reported 
high levels of quality of life and overall health despite his paraplegia. These high quality of life scores 
in the face of physical impairment may have been affected by the fact that he had survived his 
childhood cancer.  
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4.2 Range of salvage and supportive treatments 
There is no established standard of care for patients with recurrent brain tumours or for partial 
responders. In this context it is highly appropriate that patients receive novel therapies with 
uncertain efficacy profiles as long as the impact on HRQOL is assessed and there is a low threshold 
for discontinuing treatment if a negative impact on HRQOL becomes evident. The patients in this 
cohort received a variety of salvage therapies in addition to re-irradiation. All patients were 
reviewed at a neuro-oncology multidisciplinary meeting prior to salvage treatment. Fogh and 
colleagues [1] established that 35Gy in 10 fractions was an effective salvage treatment for 147 
recurrent high grade gliomas patients with a median survival time of 11-months after re-irradiation. 
The regime was well tolerated with no patients demonstrating clinically significant acute toxicity. 
One patient in the Fogh trial who received 40Gy experienced severe headaches 4-months post re-
irradiation, which could have been due to radiation necrosis. This finding is in agreement with a 
previous study by Shepherd and colleagues [97] who treated 36 patients with hypo-fractionated 
radiation to doses ranging from 20Gy to 50Gy in 5Gy per day fractions. They found that a total dose 
of >40Gy was a major predictor of radiation necrosis with 36% of patients experiencing radiation 
induced brain damage. The majority of patients in this thesis received re-irradiation following the 
Fogh protocol. No patients experienced confirmed radiation necrosis as a result re-irradiation. 
However, GBM01 did suffer from progression of symptoms without radiologically confirmed tumour 
progression; this may have been as a result of radiation induced brain damage, or prolonged 
exposure to chemotherapy. Radiation necrosis is a late effect (taking months to years to present). It 
is therefore important that as patients are surviving longer these effects are monitored.  
Marks and colleagues [98] conducted a review of normal tissue dose/volume tolerances in order to 
produce a guide to normal tissue complication probability models in clinical practice. These 
recommendations give a guide to the likelihood of an adverse reaction occurring if a tolerance dose 
is exceeded. These recommendations are internationally recognised as the gold standard for organ 
at risk tolerances. However, in the setting of recurrent high grade gliomas, depending on the 
location of the tumour, it is necessary to exceed these tolerances in order to achieve a therapeutic 
dose of radiation. Viewed in the context of limited overall survival and the negative impact that 
tumour progression has on HRQOL, higher risks of radiation induced complications are more 
acceptable. RTOG 1205, which is currently recruiting; is a stage II RCT, evaluating Bevacizumab alone 
or with concurrent re-irradiation using the Fogh protocol. As part of the protocol RTOG 1205 
stipulates acceptable radiation doses to normal tissues which exceed those recommended by Marks. 
RTOG 1205 tolerances are adhered to at ARO in this patient cohort to ensure morbidity from 
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treatment was acceptable but sufficient radiation was delivered to have some efficacy. For example 
Marks stipulates that if a point in the brainstem receives a dose of less than 64Gy there is a less than 
5% chance of permanent cranial neuropathy. RTOG stipulates that where necessary to achieve a 
therapeutic dose the brainstem can receive a total of 90Gy from primary and secondary treatments. 
For a majority of patients in this trial it was not necessary to exceed tolerances stipulated by Marks. 
However, patient GBM04’s brainstem received a total of 87Gy which is within RTOG limits but 
exceeds those of Marks. Although the survival from re-irradiation was short for patient GBM04 the 
area that was re-irradiated did partially respond and necrosis did not develop in this area in that 
short period of time. 
The wide range of chemotherapies offered as salvage depended on time to recurrence, patient age, 
comorbidities but also on government and health insurer funding. Three patients (GBM01, GBM03 
and GBM06) were prescribed Temozolomide as salvage chemotherapy. A meta-analysis of 15 phase 
II clinical trials, including 902 recurrent GBMs demonstrated an overall survival at 1-year of 36.4% (CI 
26.9-47.1%) [51]. Two of the patients (GBM01 and GBM03) discontinued Temozolomide and were 
prescribed Bevacizumab and Irinotecan. GBM01 had stable disease for a five month period but she 
developed thrombocytopenia; GBM03 experienced no significant toxicity however her disease 
progressed after five months. GBM06 continues to take Temozolomide without significant toxicity 
and has stable disease. 
Three small phase II trials investigated the efficacy of Bevacizumab and Irinotecan as a salvage 
chemotherapy regime for recurrent GBM. The authors of the trials, reported mean progression free 
survival of 5 months (5.1 to 5.3 months) and overall survival of 8.8 months – 9.3 months [60]. Three 
patients in this thesis received Bevacizumab and Irinotecan, two of these patients responded very 
well. GBM01 experienced nine months of progression free survival while on Bevacizumab and 
Irinotecan salvage chemotherapy and is still alive 15 months after recurrence. GBM03 had a 
radiological response to Bevacizumab and Irinotecan after two-months of the therapy; she continues 
to respond to this therapy and is alive ten months after recurrence. GBM04 however deteriorated 
rapidly after commencing this therapy and therefore it was discontinued before any radiological 
assessment of response was made. Bevacizumab and Irinotecan are not on the PHARMAC schedule 
in New Zealand for GBMs and are therefore not subsidised by the Ministry of Health and many 
health insurers also do not cover the cost. Paying for their own chemotherapy may pose a large 
financial burden on patients with limited gain as the efficacy of these treatments in GBM is currently 
unknown. Patient GBM05 had been referred for Bevacizumab and Irinotecan however he could not 
afford to pay for it. The advantage of taking part in clinical trials is that drugs are provided free of 
88 
 
charge and hence the financial burden of novel therapy is not captured [80]. A third of patients in 
the Fogh study [1]also received chemotherapy at some time in their salvage treatment. The authors 
did not find a survival advantage when combining chemotherapy with hypo-fractionated radiation 
therapy. Interestingly, only four (2.7%) patients in this trial received Bevacizumab plus Irinotecan 
chemotherapy. Three trials reported a mean overall survival of 11-months for hypo-fractionated 
radiation therapy alone and 9-months for Bevacizumab plus Irinotecan chemotherapy alone. The 
positive response of two patients in this thesis to Bevacizumab plus Irinotecan chemotherapy may 
indicate that combining this chemotherapy regimen with hypo-fractionated radiation therapy could 
be advantageous.  
At the time of writing this thesis five of the seven patients were still alive. With increasingly effective 
salvage treatments patients are living longer with recurrent high grade glioma. For example patient 
GBM01 is nearly seven years post initial diagnosis and 15-months post recurrence. Longer survival 
times highlight the need for supportive therapy to minimise the physical and psychosocial impact of 
living with a brain tumour for patients and their family.  
Posttraumatic stress disorder is a well-known syndrome experienced by people who have had a 
traumatic life experience, such as combat soldiers, more recently, the term has been applied to 
cancer patients [96]. Research by Hobbie and colleagues [96] found that 20-percent of adult 
survivors of childhood cancer met criteria for posttraumatic stress disorder. Parents of paediatric 
patients were also at risk of developing posttraumatic stress disorder as a result of their child having 
a life threatening disease. Patients with a poor prognosis are at greater risk of psychosocial distress. 
As a result of a cancer diagnosis and its treatment patients experienced symptoms of post-traumatic 
stress disorder at a rate of 4% to 19% in a trial conducted by Vachon and colleagues [99]. Zabora et 
al [94] conducted a study aimed at determining the prevalence of psychological distress in a large 
group of cancer patients (n=4496) using the ‘Brief Symptom Inventory’. They reported that the rates 
of some degree of depression and anxiety were higher in patients with a brain tumour (53%) 
compared with other cancer diagnoses (35.1%) [94]. 
 Psychosocial interventions can help cancer patients to cope better with very distressing situations. 
The type of intervention will vary dependent on the stage in the cancer journey the patient is at, the 
prognosis of their cancer, and their inherent personality and support network [99]. One patient 
(GBM06) was referred to a psychiatrist for intervention as she was suffering from severe anxiety 
attacks at six weeks post re-irradiation. This was found to be a helpful intervention for her. Hospice 
counselling support services were also utilised by GBM04 and his family towards the end of his 
cancer journey. One domain of the EORTC questionnaire is that of psychosocial problems and covers 
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many different aspects such as ‘did you worry?’, ‘were you concerned about disruption to family 
life?’ ‘has your physical condition or medical treatment caused you financial difficulties?’. All 
patients expressed at least a little psychosocial distress however, many patients did not receive any 
kind of formal intervention. As discussed above, interventions need to be appropriate for the patient 
and will probably need to adapt over time as their needs change. Addressing psychosocial issues of 
high grade glioma patients remains an area of importance as dealing with and decreasing 
psychosocial distress will improve the HRQOL of patients and their families [80].  
Rehabilitation tends to be reasonably limited in patients with high grade glioma, however with 
increasing survival times this may be an area that needs to be explored. It is important to 
understand the needs of patients and their families throughout the cancer journey. There is 
currently limited research into the need for supportive interventions and their effectiveness in high 
grade glioma patients. Piil and colleagues [100] analysed the need for rehabilitation of patients with 
high grade glioma and are currently conducting a trial to assess the impact of rehabilitation on the  
quality of life of high grade glioma patients and their caregivers.  
The physical symptoms of a brain tumour vary depending on the location and size of the tumour. 
Most patients will need to use Dexamethasone at some stage to reduce brain swelling, resulting in a 
number of acute side effects such as headaches, nausea and vomiting [101]. Prolonged use of 
Dexamethasone also causes peripheral weakness [101]. Many of the patients in this thesis reported 
feeling ‘unsteady on their feet’, ‘trouble taking a short walk outside of the house’ or felt limited in 
activities of daily living. One patient (GBM01) was referred to physiotherapy; although it is unclear if 
this was helpful. If supportive care interventions such as physiotherapy and occupational therapy are 
effective it may relieve some of the burden from the caregivers and give patients an improved 




4.3 Health Related Quality of Life  
Although this observational study did not aim to establish the efficacy of salvage treatments, some 
patients derived benefit from salvage treatment in terms of stabilising or reversing tumour 
progression and its associated symptoms. The effect of salvage treatment was reflected in clinically 
meaningful increases or maintenance of overall health and quality of life scores and gave patients a 
window of opportunity to do the things that are important to them and their family. Although an 
increase in overall survival of several months may not seem ground breaking, it must be viewed in 
the context of the dismal prognosis of this disease whereby every month is valuable as long as it is 
not achieved at the cost of HRQOL. Ernst-Stecken and colleagues [102] prospectively evaluated the 
efficacy, side effects and quality of life in 15 patients with malignant glioma treated with hypo-
fractioned radiation therapy. This trial delivered 35Gy over 5 fractions, 3 fractions per week [102] 
and was conducted before Fogh established 35Gy in 10 fractions as a standard dose regime [1]. 
Quality of life was measured using EORTC QLQ-C30 and BN-20 questionnaires; scores were stable in 
two thirds of patients for 9-months. No acute toxicity occurred during treatment necessitating an 
increase in steroids. Progression free survival rates at 6 and 12 months were 75% and 53% 
respectively. The Ernst-Stecken trial also demonstrated that re-irradiation can prolong survival as 
well as preserve quality of life [102]. Fogh reported similar rates of progression free survival of 81% 
and 50% at 6 and 12 months respectively but did not include quality of life measures in their trial [1]. 
Osoba and colleagues [8] conducted a phase II trial where 109 patients received Temozolomide and 
a phase III trial where 89 patients received Temozolomide and 90 patients received Procarbazine. 
HRQOL measurements were carried out as a component of these two studies. The phase II trial 
reported 6-month progression free survival of 20%. The phase III trial reported 6-month progression 
free survival of 21% and 7% for Temozolomide and Procarbazine respectively. Patients who received 
Temozolomide and who remained progression free reported improved or maintained HRQOL scores. 
In contrast, patients in the Procarbazine arm who remained progression free reported deterioration 
in most HRQOL domains due to the toxicities of Procarbazine. These findings demonstrate that 
stability or response of the tumour to therapy can be beneficial to HRQOL but only where the 
therapy has a modest toxicity profile. Further stage III clinical trials need to establish which of the 
novel targeted salvage treatments are most likely to benefit high grade glioma patients.  
Over the course of re-irradiation most patients in this thesis experienced stable or a slight decrease 
in overall health and quality of life. Symptoms of fatigue, feeling a little tired or needing to rest 
increased in most patients. Symptom scores varied between patients, depending largely on their 
baseline symptoms and location of their tumour. Cranial irradiation often causes headaches, nausea 
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and vomiting, largely as a result of radiation induced swelling of the brain [101]. Perhaps due to 
more conformal treatment techniques and/or supportive pharmaceutical interventions such as 
Dexamethasone and anti-emetics these were not common issues for this cohort of patients. Whilst 
the patient is on treatment, the treatment radiation therapists are primarily responsible for patient 
care as they interact with them daily. The wide range of symptoms that patients experienced 
demonstrates the importance of an awareness of and questioning the patient about possible side 
effects. Building a good rapport with patients is equally important so that patients feel comfortable 
talking about any issues that they are having so that appropriate help such as practical support or 
supportive medications can be implemented in a timely manner.  
Collecting quality of life and overall health data on patients with high grade glioma is challenging. 
Due to cognitive and physical impairments of the disease patients may not be able to complete QOL 
questionnaires. Due to progressive disease patients GBM02 and GBM04 required assistance from 
either the author or their spouse to complete the EORTC questionnaires towards the end of their 
journey. Sneeuw and colleagues [103] investigated if significant others could be used as proxy rates 
for quality of life scores in patients with primary or recurrent brain cancer. A total of 103 pairs of 
patients and significant others completed EORTC QLQ-C30 and BN20 questionnaires at the time of 
their initial clinic visit, one week later and another at least 3-weeks later. Scores by the patients and 
their proxies were compared. A high level of agreement was found, approximately 60% of responses 
were identical, and 90% of scores were within one response category. This research indicates that 
although proxy ratings are not a perfect surrogate for patients self-rating they may be useful in 
patients where participation would otherwise be lost.  
In the previously described RCT by Stupp, that set the standard for treatment of newly diagnosed 
GBM, the HRQOL was a secondary endpoint. At baseline 490 (86%) of patients completed EORTC 
QLQ-C30 and BN-20 questionnaires. Despite the large numbers at the outset of this trial by the 
fourth follow-up only 51 (68%) patients completed their questionnaires. Therefore HRQOL analysis 
was only done based on the first four follow-ups [88]. One problem that this high drop-out 
presented is that any improvement in HRQOL from baseline maybe due to so called survivorship and 
not an improvement in HRQOL at an individual level. Using patients as their own controls does 
mitigate this problem somewhat [8]. In this thesis HRQOL life data using EORTC scores during and 
after salvage treatment are compared to baseline EORTC scores for each patient and not as a way to 
compare scores between patients.   
Due to the very limited survival of this patient cohort it is also important that any time burden 
associated with filling in questionnaires is minimised. In the original validation work the EORTC QLQ-
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C30 and BN20 questionnaires were completed in approximately 11 minutes by patients  [87,104]. 
Most patients in this thesis were able to complete the questionnaires while waiting for their 
treatment or follow-up appointment. Although in the design of this study the burden of participation 
to patients was minimised, two eligible patients did decline participation due to high levels of 




4.4. Limitations of the study 
Although this study has given an insight into the unique experiences of seven patients receiving re-
irradiation for recurrent high grade glioma there are some limitations to this project, which are 
addressed below. 
Cohort demographics 
Although there were only seven patients in this study, the patients varied with respect to patient-
related (age, gender, personal circumstances) and treatment-related factors (time to relapse, type of 
and response to salvage treatment). The experience of this small cohort would have been influenced 
by the fact that all of the patients were treated in a private clinic rather than in a public hospital. 
These patients were likely of a higher socioeconomic class and experienced fewer environment 
pressures such as the need to keep working and/or having strong support networks. An example of 
this is patient GBM04 whose wife resigned work to look after him and could afford a mobility van. 
This cohort also lacked in ethnic diversity, all patients identified themselves as NZ European, and 
English was the first language of all seven patients. One eligible patient declined to participate in the 
study because of communication difficulties. Although he was a New Zealand citizen, he was born in 
Russia and did not speak English fluently. Research suggests that minority ethnic groups can be at 
elevated risk of psychosocial distress from cancer, therefore distress may be under-reported in this 
patient cohort as all patients were NZ European [99]. 
Short follow-up time 
Ethics approval for this study was granted in August 2014, patient recruitment and data collection 
commenced in September 2014. In order to provide sufficient time for data analysis, data collection 
for this thesis ceased in December 2015. The final patient was recruited into this study in June 2015; 
this gave a minimum follow-up period of five months. Five of the seven patients in this study are still 
alive; it would be good to continue to follow these patients in order to gain more insight into the 
journey of this recurrent high grade glioma cohort. 
Not collecting CTCAE scores 
The original study methodology stipulated that patients complete the EORTC QOL questionnaires 
and the author scores the physical symptoms of the tumour and side effects of radiation according 
to the CTCAE scale. Using the CTCAE scale was stopped very soon after patient GBM01 started the 
study for a number of reasons. To minimise time in the department and disruption to clinical staff, 
patients were given the EORTC QOL questionnaires on arrival at the department and completed 
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these in the waiting room. However, the CTCAE scores required conversation between the patient 
and author and could not be done with sufficient confidentiality in the waiting room. Therefore, the 
author either had to complete the CTCAE scores in the treatment room or during the consultation 
visit with the Radiation Oncologist. This scenario disrupted the flow of the interactions and added a 
formality to an otherwise relatively relaxed environment. Bringing the patient into a separate clinic 
room to do the CTCAE questions added to the time that the patient had to spend in the department. 
This was felt to be an unnecessary burden on the patient.  
In addition, the domains covered by the CTCAE overlap with those of the EORTC QOL questionnaires. 
Most of the questions were double ups of the EORTC questionnaires and graded them on a different 
scale which did not add more insight into the patient journey. We therefore abandoned the use of 
CTCAE questionnaires for this study. Walker and colleagues [105] found that doubling up on 
questions resulted in poorer patient compliance with the trial and decreased their willingness to 
participate. 
Missed appointments 
All patients to be treated for recurrent GBM were to be screened for eligibility by the author. Prior 
to the planning CT scan all patients were reviewed at a pre-CT triage meeting with bookings staff and 
pre-treatment (CT and planning) radiation therapists. At this time potential patients would have 
been identified and the author notified. If the patient met the eligibility criteria it was her 
responsibility to attend the CT in order to provide information about the study to the patient and 
attend their treatments when questionnaires needed to be completed.  
Incomplete EORTC questionnaires 
Patients completed the EORTC QOL questionnaires at the time of their follow-up appointments 
rather than posting them out to increase the response rate. It also meant that their responses could 
be correlated immediately to clinical observations and follow-up MRIs or a new salvage therapy 
regimen could be implemented if warranted. Although the bookings team was to notify the author 
of any patients who were scheduled to undergo a CT scan or for follow-up appointments, this did 
not always happen. Patients were informed about the trial at the time of their CT scan but those that 
were missed at their CT scan were given the information about the study on the first day of 
treatment. At their second treatment they were asked for consent, and if given, baseline scores 
were recorded. The author was not always notified of follow-up appointments. Patient schedules 
were monitored regularly but some of these were altered at the last minute and missed by the 
author. Although missed information was recovered to some extent from reading clinic notes and 
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discussing the patient with the radiation oncologist, this was less informative than from completed 
EORTC QOL questionnaires and attending a consultation.  
Although Auckland Radiation Oncology was very supportive of this research sometimes it was not 
possible to release the author from her (full time) clinical duties in order to attend follow-ups. For 
the most part, she was able to delegate other clinical staff to hand out the EORTC QOL 
questionnaires.  
Another barrier to completing EORTC questionnaires was the deteriorating health of some patients 
who found the EORTC questionnaires a burden to complete. For patients whose vision was a 




4.5 Future research  
This observational study has highlighted the need for future research in many areas for patients with 
recurrent high grade glioma.  
 The literature review compiled for this thesis has highlighted the need for more randomised 
controlled clinical trials to find better therapy combinations for relapsed high grade glioma 
patients that increase overall survival whilst maintaining quality of life. Following the patients in 
the study cohort on their journey through and beyond salvage treatment reinforced the need for 
documenting HRQOL using the EORTC C30 and BN20 questionnaires.  
 With the increased survival times of relapsed high grade glioma patients it is important that 
further studies allow for a long enough follow-up time to better understand and manage HRQOL 
issues at all stages of their journey.  
 Future research may benefit from canvassing the perspective of family members/carers as that 
may differ from the patient’s perspectives. This could be done by administering HRQOL 
questionnaires separately but also through semi-structured interviews with individual family 
members. This would also allow the researcher to identify issues of importance to the family 
members/carers and perhaps suggest referral to support services to help them cope better with 
looking after a high grade glioma patient.  
 Dr Falkov at Auckland Radiation Oncology is the only radiation oncologist who uses hypo-
fractionation as a salvage treatment for these patients. An inventory of salvage therapy practice 
for recurrent high grade glioma patients across New Zealand would be useful, particularly if 
survival and HRQOL data between salvage treatments could be compared.  
 A greater involvement in international trials would be beneficial for both patients and staff. For 
example, Auckland Radiation Oncology follows the RTOG 1205 protocol for re-irradiation, 
however they are not accredited and do not administer Bevacizumab according to the trial 
protocol. 
 It is important that future research goes above and beyond oncologic interventions such as 
radiation and chemotherapy and explores potential rehabilitation options such as 
physiotherapy. 
 In order to minimise the number of missed appointments, a more automated way of alerting the 
researcher of study patients’ appointments in the department must be put in place. 
All of these above-mentioned research suggestions would add to the knowledge of recurrent high 
grade glioma patients which, over time, may result in clinically meaningful increases in HRQOL and 
overall survival. This research has highlighted the insight that an in depth observational study can 
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add to understanding the overall journey of patients and their families over and above survival data 
and EORTC questionnaire scores. It would be very beneficial to continue to follow this patient group 
in order to gain an insight into their full journey. Future observational studies of this nature would 
also be recommended in order to enrich the body of knowledge across a wider patient group 






4.6 Conclusion  
This thesis describes the seven journeys of seven relapsed high grade glioma patients and their 
families through salvage therapy and beyond. The author used a prospective observational study 
design which combined regular validated quality of life questionnaires, filled in by the patient, with 
the author attending consultations of patients with their radiation oncologist, referring to patient 
notes as well as gaining information from CT and MRI scans.  Using a variety of ways to collect 
information about the patients allowed the author to build up a detailed picture of the patients, 
their life before the cancer diagnosis and their health and quality of life, during and after salvage 
treatment.  
The seven journeys of the seven patients in the cohort were unique. Patient expectations regarding 
health and quality of life throughout salvage therapy depended on a combination of age, stage in 
life, time to relapse, severity of disease symptoms and the extent to which they had accepted their 
prognosis. Hypo-fractionated salvage re-irradiation resulted in a small decrease in health and quality 
of life during the two weeks of treatment for all patients, because of the adverse effect of re-
irradiation of the brain, such as brain compression due to oedema. However, in the months 
following treatment, the health and quality of life scores improved and stabilised for most patients. 
Most of the patients had a partial response to salvage radiation therapy, suggesting that hypo-
fractionated radiation therapy may be a salvage therapy option for at least some patients with 
relapsed high grade glioma. A major cost of salvage radiation therapy for patients is the disruption to 
everyday life due to the logistics of attending daily treatment sessions. Hypo-fractionated radiation 
therapy, delivered over two weeks, is more suited than the much longer conventional fractionation 
regimens. 
Limitations of the study include the cohort demographics and the short and varied follow-up time. 
Because of the time constraints of an honours thesis project, only a small number of patients 
participated and were followed up for a short period of time (between five and 15 months). All 
patients attended a private clinic and most likely belonged to a higher socioeconomic group where 
the pressures of having to keep working to provide for their family were less of an issue. The cohort 
also lacked ethnic diversity as all patients identified themselves as NZ European. The severity of 
treatment-related side effects measured using the CTCAE scale was abandoned for one patient 
because of the burden of an additional interview and the similarities of items of the CTCAE and 
EORTC quality of life questionnaires. Side effects were discussed during consultations with the 
radiation oncologist, which the author attended.  
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The patients themselves were supposed to fill in quality of life questionnaires at the start, during 
treatment and at follow-up consultations. This did not happen for all time points for all patients 
because the author was not always advised of a change in follow-up appointments or could not be 
released from clinical duties to hand out the questionnaires and in some cases patients were too 
unwell to fill them in. 
Overall, the study suggests that hypo-fractionated radiation therapy combined with chemotherapy 
as a salvage treatment for recurrent high grade glioma may be a good option for some recurrent 
high grade glioma patients. The study further identifies the need for more research into the 
wellbeing of high grade glioma patients and the best ways to support them in coping with the 
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Appendix A: Primary Chemotherapy Regimes  
Primary treatment: standard fractionation & chemotherapy 





% PFS 6 
m 
% OS 1 
y 
% OS 2 
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Stupp 2009 









































Stage II RCT Stupp 70 13.6 19.6 88% 
  
 p<0.005 Stupp EORTC-Canadian cohort 110 7.6 21.1 58% 
  
Poulsen 2014 Review (10 studies) Stupp + BEV 
 
7.3-14.2 11.7-23 52-85% 
  
Chauffert 2014 
Stage II RCT 
No p values 
reported 
BEV+IRI then RT+conTMZ then BEV 60 7.1 11.1 50% 
  
Stupp 60 5.2 11.1 50%   
Hofland 2014  
Stage II RCT  
p=0.56 
BEV+IRI +con RT+ adj chemo 31 7.7 
    
BEV +TMZ+con RT+ adj chemo* 32 7.3 
    
Vredenburgh 2011 Stage II single arm Stupp +BEV adj BEV/TMZ/IRI 75 14.2 21.2 
   






Uhm 2011 Stage II single arm RT adj  Gefitinib 96 
   
54% 
 
Chakravarti 2014 Stage II single arm RT adj Gefitinib 119 4.9 11.5 40% 
  
Peereboom 2010 Stage II single arm Stupp +ERL 72 2.8 8.6 37% 
  
Prados 2009 Stage II single arm Stupp+ERL 65 7.2 18.6 60% 65% 
 
Butowski 2011 Stage II single arm Stupp+Enzastaurin  66 8.4 17.3 65% 76% 
 




Appendix B: Salvage chemotherapy regimes 
Secondary treatment: chemotherapy 
References Study Design Chemotherapy Regimen No. of Pts Mean PFS  Mean OS  % PFS 6m 
Chen 2013   





Norden 2008  Stage II single arm BEV 34 5.1 9.1 
 
Reardon 2011  
Stage II RCT  
(p=0.0356) 
BEV + metronomicTMZ 10 0.96 2.9 
 
BEV+metronomic ETOP  13 1.9 4.4 
 
Hasselbalch 2010  
Stage II RCT  
(p=0.004) 
BEV+cetuximab+  IRI 32 3.7 7 33% 
BEV+cetuximab+  IRI + carbo  43 4 7.5 29% 
Moller 2012 Stage II single arm BEV+Irinotecan 85 5.2 
  
Gil 2012 Stage II single arm BEV+Irinotecan 94 5.1 8.8 
 
Vredenburgh 2007  
Stage II RCT  
No p values 
reported 




Reardon 2011 Stage II single arm BEV +Carboplatin+Irinotecan+BEV (BEV failed) 25 2.3 5.8 16% 
Reardon 2012 Stage II single arm BEV+Carboplatin+ Irinotecan+BEV (BEV naïve) 40 
 
8.3 47% 
Reardon 2005 Stage II single arm IRI+celecoxib 34 2.6 7.4 25% 
Puduvalli 2008 Stage II single arm IRI +Thalidomide 32 3 8.4 25% 
 
 
Fadul 2008 Stage II single arm IRI+ Thalidomide 16 
 
4.6 19% 





Stage II single arm BEV+Erlotinib 25 4.2 9.8 29% 
Peereboom 2013 Stage II single arm Erlotinib +Sorafenib 56 0.5 5.7 14% 
van den Bent 2013  





TMZ (27)or Carmustine (29) 56 
 
7.3 24% 
Raizer 2010 Stage II single arm Erlotinib 38 2 6 3% 
Reardon 2011 Stage II single arm Erlotinib+Sirolimus 32 1.6 6.1 3% 
Aoki 2010 Stage II single arm Carboplatin +ETOP + IPhospamide 42 4 
 
35% 
Franceschi 2004 Stage II single arm Carboplatin+ETOP (GBM) 25 4 10 33% 
Raymond 2008 Stage II single arm Imatinib 112 1.7 5.2 16% 
Reardon 2005 Stage II single arm Imatinib+HydroxyUrea 33 3.4 
 
27% 
Reardon 2009 Stage II single arm Imatinib+HydroxyUrea 231 1.3 6.1 11% 
Kreisl 2012 Stage II single arm Vandetanib 32 1.3 6.3 7% 
Zustovich 2013 Stage II single arm Sorafenib+TMZ 43 7.4 
 
26% 
Friday 2012 Stage II single arm Bortezomib+Vorinostat 37 1.5 3.2 0% 
 
 













Appendix E: Karnofsky Performance Status  
The Karnofsky performance status index [106] 
General category  Index  Specific criteria 
Able to carry on normal activity no special 
care needed. 
100 Normal, no complaints, no evidence of 
disease  
90 Able to carry on normal activity, minor signs 
or symptoms of disease  
80 Normal activity with effort, some signs of 
symptoms of disease  
Unable to work, able to live at home and 
care for most personal needs, varying 
amount of assistance needed. 
70 Cares for self, unable to carry on normal 
activity or to do work 
60 Requires occasional assistance from others 
but able to care for most needs  
Unable to care for self, requires institutional 
or hospital care or equivalent, disease may 
be rapidly progressing.  
50 Requires considerable assistance form others 
and frequent medical care  
40 Disabled, requires special care and assistance   
30 Severely disabled, hospitalisation indicated, 
death not imminent  
20 Very sick, hospitalisation necessary, active 
supportive treatment necessary  























Appendix H – List of abbreviations 
EOTRTC The European Organisation for Research and Treatment of Cancer 
CTCAE Common Terminology for Adverse Events 
GBM Glioblastoma multiforme 
WHO World health organisation  
HRQOL Health-related quality of life 
CT Computed tomography 
MRI Magnetic resonance imaging  
PET Positron emission tomography  
MET 11C-methionine 
FET 18F-fluoroethyl-L-tyrosine 
VMAT Volumetric arc therapy 
RCT Randomised clinical trial 
RT Radiation therapy  
MGMT O-6-methylguanine-DNA methyltransferase 
VEGF Vascular endothelial growth factor 
PFS Progression free survival 
OS Overall survival 
RTOG Radiation Therapy Oncology Group  
ARO Auckland Radiation Oncology  
CCNU Lomustine  
FACT-G Functional Assessment of Cancer Therapy-General 
MDASI MD Anderson Symptom Inventory 
QLQ-C30 Questionnaire core-30 
BN-20 Brain cancer module - 20 
KPS Karnofsky Performance Score 
BRT Bachelor of Radiation Therapy  
AA Anaplastic astrocytoma 
n Number 
 
 
 
